var title_f29_35_30256="Left iliac artery aneurysm on 3D computed tomography";
var content_f29_35_30256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left iliac artery aneurysm on 3D computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 638px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30256=[""].join("\n");
var outline_f29_35_30256=null;
var title_f29_35_30257="Gingival hyperplasia";
var content_f29_35_30257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingival hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30257=[""].join("\n");
var outline_f29_35_30257=null;
var title_f29_35_30258="Patient information: Treatment for hepatitis C (The Basics)";
var content_f29_35_30258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/39/32370\">",
"         Patient information: Hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/22/4451\">",
"         Patient information: Latest medicines for hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/45/1746\">",
"         Patient information: Vaccines when you have hepatitis C (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/4/17478\">",
"         Patient information: Hepatitis C (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Treatment for hepatitis C (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H92374932\">",
"      <span class=\"h1\">",
"       Should I be treated for hepatitis C?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You and your doctor will need to decide together whether you should be treated. Treatment is not right for everyone. To decide on treatment, you and your doctor will need to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What type of hepatitis C you have (there are 4 types)",
"       </li>",
"       <li>",
"        How old you are and how long you have had hepatitis C",
"       </li>",
"       <li>",
"        How much liver damage you have",
"       </li>",
"       <li>",
"        What other health problems you have, such as depression or HIV",
"       </li>",
"       <li>",
"        Whether you use a reliable form of birth control",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92374949\">",
"      <span class=\"h1\">",
"       How is hepatitis C treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment depends on what type of hepatitis C a person has. Treatment usually lasts 6 months to a year.",
"     </p>",
"     <p>",
"      People with",
"      <strong>",
"       all types",
"      </strong>",
"      of hepatitis C who get treated usually get these 2 medicines:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Peginterferon (sample brand names: Pegasys&reg;, PegIntron&reg;) &ndash; This medicine comes in a shot that you give yourself once a week.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"         Ribavirin",
"        </a>",
"        (sample brand names: Copegus&reg;, Rebetol&reg;) &ndash; This medicine comes in a pill comes you take 2 times a day with food.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with",
"      <strong>",
"       type 1 hepatitis C",
"      </strong>",
"      who are getting treated",
"      <strong>",
"       ALSO",
"      </strong>",
"      often get 1 of these 2 medicines:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"         Boceprevir",
"        </a>",
"        (brand name: Victrelis",
"        <sup>",
"         TM",
"        </sup>",
"        )",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"         Telaprevir",
"        </a>",
"        (brand name: Incivek",
"        <sup>",
"         TM",
"        </sup>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Either 1 of these medicines greatly increases the chances that a person will be cured. But both medicines work only on type 1.",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"       Boceprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"       telaprevir",
"      </a>",
"      must be taken 3 times a day with food that has some fat in it. Each dose must be taken about 8 hours apart.",
"     </p>",
"     <p>",
"      If you are being treated for hepatitis C, it is very important that you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take",
"        <strong>",
"         ALL",
"        </strong>",
"        your medicines exactly how your doctor or nurse tells you to",
"       </li>",
"       <li>",
"        Never skip doses",
"       </li>",
"       <li>",
"        Never stop any of your medicines unless your doctor or nurse tells you to",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92374966\">",
"      <span class=\"h1\">",
"       What happens if I do not take hepatitis medicines as directed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take these medicines the wrong way, you can end up doing yourself more harm than good. In people who skip doses or do not take all their medicines, the hepatitis C virus can quickly become &ldquo;resistant.&rdquo; That means that the virus learns to outsmart the medicines, and so the medicines will not work.",
"     </p>",
"     <p>",
"      To help you remember to take all of your medicines at the right time, use special reminders called &ldquo;memory aids.&rdquo; For instance, use a &ldquo;talking&rdquo; pill box or a wrist watch that can be set to tell you whenever it&rsquo;s time to take your pills.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92374981\">",
"      <span class=\"h1\">",
"       Do the medicines for hepatitic C cause side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, they often do. Peginterferon and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"       ribavirin",
"      </a>",
"      can make you tired, depressed, or feel like you have the flu. These medicines can also cause a problem called anemia, which is when you do not have enough red blood cells to carry oxygen around your body.",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"       Boceprevir",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"       telaprevir",
"      </a>",
"      can also cause anemia, and they can cause a rash.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92374996\">",
"      <span class=\"h1\">",
"       What should I do if I get side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get any side effects that bother you, tell your doctor or nurse. If you get a rash, call your doctor right away. Your doctor or nurse will want to see your skin so he or she can decide how bad the rash is. He or she will also want to know right away if you start feeling light-headed or extremely weak or breathless. These can be signs of severe anemia.",
"     </p>",
"     <p>",
"      In very rare cases, people need to stop taking their medicines because of side effects. But",
"      <strong>",
"       DO NOT STOP TAKING YOUR MEDICINES",
"      </strong>",
"      because of side effects until you speak with your doctor or nurse. Only he or she can really tell if you need to stop the medicines. Besides, your doctor or nurse might have a way to deal with the side effects so that you can keep taking the medicines.",
"     </p>",
"     <p>",
"      Even if your doctor can&rsquo;t make your side effects go away completely, remember that you only need to take these medicines for a while. If you put up with some side effects, there is a good chance you will cured.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375011\">",
"      <span class=\"h1\">",
"       Will I be cured?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you take your medicines exactly the way you are supposed to, the chances of being cured are good.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        People with type 1 who take peginterferon,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"         ribavirin",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"         boceprevir",
"        </a>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"         telaprevir",
"        </a>",
"        are cured 70 to 80 percent of the time.",
"       </li>",
"       <li>",
"        People with type 2 or 3 who take peginterferon and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"         ribavirin",
"        </a>",
"        are cured 80 percent of the time.",
"       </li>",
"       <li>",
"        People with type 4 who take peginterferon and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"         ribavirin",
"        </a>",
"        are cured 50 to 70 percent of the time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      At least 6 months after you finish treatment, your doctor or nurse will check to see if you are cured. If you are not cured after your first course of treatment, he or she might suggest trying treatment again or waiting for new medicines to come out. If you have type 1 and got treated before",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/1/20501?source=see_link\">",
"       boceprevir",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"       telaprevir",
"      </a>",
"      was available, your doctor might suggest you get treated with peginterferon,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and boceprevir or telaprevir.",
"     </p>",
"     <p>",
"      This article has basic information on the medicines used to treat hepatitis C. For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines, and what to do if you forget to take a dose at the right time. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods. You should also ask your pharmacist for the FDA Medication Guides that come with the medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H92375026\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       Patient information: Hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/22/4451?source=see_link\">",
"       Patient information: Latest medicines for hepatitis C (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/45/1746?source=see_link\">",
"       Patient information: Vaccines when you have hepatitis C (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       Patient information: Hepatitis C (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/35/30258?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86452 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30258=[""].join("\n");
var outline_f29_35_30258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92374932\">",
"      Should I be treated for hepatitis C?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92374949\">",
"      How is hepatitis C treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92374966\">",
"      What happens if I do not take hepatitis medicines as directed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92374981\">",
"      Do the medicines for hepatitic C cause side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92374996\">",
"      What should I do if I get side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375011\">",
"      Will I be cured?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92375026\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/22/4451?source=related_link\">",
"      Patient information: Latest medicines for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/45/1746?source=related_link\">",
"      Patient information: Vaccines when you have hepatitis C (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_35_30259="Prenltrasound image of umbilical cord pseudocyst and angiomyxoma";
var content_f29_35_30259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of umbilical cord pseudocyst and angiomyxoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giant umbilical cord pseudocyst (C) associated with an angiomyxoma (asterisk). Intrauterine aspiration had been performed twice, with reaccumulation of the cystic fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Edgardo Corral, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30259=[""].join("\n");
var outline_f29_35_30259=null;
var title_f29_35_30260="Nabilone: Pediatric drug information";
var content_f29_35_30260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nabilone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=see_link\">",
"    see \"Nabilone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/8/29828?source=see_link\">",
"    see \"Nabilone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2980459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cesamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F554086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cesamet&reg;;",
"     </li>",
"     <li>",
"      PMS-Nabilone;",
"     </li>",
"     <li>",
"      RAN&trade;-Nabilone;",
"     </li>",
"     <li>",
"      Teva-Nabilone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1026222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1026250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=see_link\">",
"      see \"Nabilone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;18 kg: 0.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18-30 kg: 1 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 kg: 1 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 1-2 mg twice daily (maximum: 6 mg divided in 3 doses daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cesamet&reg;: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F198766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1026253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial dose should be given 1-3 hours before chemotherapy; may be given 2-3 times/day during the entire chemotherapy course and for up to 48 hours after the last dose of chemotherapy; a dose the night before chemotherapy may be useful",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1026239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1026223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory nausea and vomiting associated with cancer chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F198769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, concentration decreased, depersonalization, depression, disorientation, dizziness, drowsiness, dysphoria, euphoria, headache, sedation, sleep disturbance, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite increased, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, abnormal dreams, akathisia, allergic reaction, amblyopia, anemia, anhydrosis, anxiety, apathy, aphthous ulcer, arrhythmia, back pain, cerebral vascular accident, chest pain, chills, constipation, cough, diaphoresis, diarrhea, dyspepsia, dyspnea, dystonia, emotional disorder, emotional lability, epistaxis, equilibrium dysfunction, eye irritation, fatigue, fever, flushing, gastritis, hallucinations, hot flashes, hyperactivity, hypertension, infection, insomnia, joint pain, leukopenia, lightheadedness, malaise, memory disturbance, mood swings, mouth irritation, muscle pain, nasal congestion, neck pain, nervousness, neurosis (phobic), numbness, orthostatic hypotension, pain, palpitation, panic disorder, paranoia, paresthesia, perception disturbance, pharyngitis, photophobia, photosensitivity, polyuria, pruritus, psychosis (including toxic), pupil dilation, rash, seizure, sinus headache, speech disorder, stupor, syncope, tachycardia, taste perversion, thirst, thought disorder, tinnitus, tremor, urination decreased/increased, urinary retention, visual field defect, voice change, vomiting, wheezing, withdrawal, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1026226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nabilone, cannabinoids, tetrahydrocannabinol, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3871553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease (may cause tachycardia and orthostatic hypotension), history of substance abuse, and those with pre-existing CNS depression; use caution with current or previous history of mental illness; cannabinoid use may reveal symptoms of psychiatric disorders. Psychiatric adverse reactions may persist for up to 3 days after discontinuing treatment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1026227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nabilone has potential for abuse and/or dependence; use caution in patients with substance abuse history; limit antiemetic therapy availability to current cycle of chemotherapy. Safety and efficacy in children have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cocaine: May enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: Cannabinoids may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2980460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3462105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Blood pressure, heart rate; signs and symptoms of excessive use, abuse, or misuse",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1026241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not fully characterized; antiemetic activity may be due to effect on cannabinoid receptors (CB1) within the central nervous system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1026243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: &sim;12.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To several active metabolites by oxidation and stereospecific enzyme reduction; CYP450 enzymes may also be involved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Parent compound: 2 hours; Metabolites: 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concertration: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (&sim;60%); renal (&sim;24%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F3462106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/8/29828?source=see_link\">",
"      see \"Nabilone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol. May cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources. Report excessive or persistent CNS changes (euphoria, anxiety, depression, memory lapse, bizarre thought patterns, excitability, inability to control thoughts or behavior, fainting); respiratory difficulties; rapid heartbeat; or other adverse reactions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chan HS, Correia JA, and MacLeod SM, &ldquo;Nabilone Versus Prochlorperazine for Control of Cancer Chemotherapy-Induced Emesis in Children: A Double-Blind, Crossover Trial,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1987, 79(6):946-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/35/30260/abstract-text/3035479 /pubmed\" id=\"3035479 \" target=\"_blank\">",
"        3035479",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dupuis LL and  Nathan PC, &ldquo;Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children,&rdquo;",
"      <i>",
"       Pediatr Drug",
"      </i>",
"      , 2003, 5(9):597-613.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/35/30260/abstract-text/12956617/pubmed\" id=\"12956617\" target=\"_blank\">",
"        12956617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tramer MR, Carroll D, Campbell FA, et al, \"Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Systematic Review,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2001, 323(7303):16-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/35/30260/abstract-text/11440936/pubmed\" id=\"11440936\" target=\"_blank\">",
"        11440936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ward A and Holmes B, &ldquo;Nabilone: A Preliminary Review of Its Pharmacological Properties and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1985, 30(2):127-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/35/30260/abstract-text/2863127 /pubmed\" id=\"2863127 \" target=\"_blank\">",
"        2863127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12991 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30260=[""].join("\n");
var outline_f29_35_30260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980459\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554086\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026222\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026250\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198735\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198722\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198766\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026253\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026239\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026223\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198769\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026226\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3871553\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026227\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299732\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198730\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198732\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980460\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462105\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026241\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1026243\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462106\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=related_link\">",
"      Nabilone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/8/29828?source=related_link\">",
"      Nabilone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_35_30261="Diverticulitis Gross";
var content_f29_35_30261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Post-partial colectomy specimen from a patient with diverticulitis shows multiple mucosal outpouchings (arrows) and thickening of the bowel wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30261=[""].join("\n");
var outline_f29_35_30261=null;
var title_f29_35_30262="Dome shaped papules";
var content_f29_35_30262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple monomorphic, dome-shaped papules and nodules that appeared on the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &copy;2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30262=[""].join("\n");
var outline_f29_35_30262=null;
var title_f29_35_30263="Hepatic hydrothorax";
var content_f29_35_30263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic hydrothorax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Andr&eacute;s C&aacute;rdenas, MD, MMSc, AGAF",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30263/contributors\">",
"     T Barry Kelleher, MD, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30263/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/35/30263/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced cirrhosis and portal hypertension have abnormal extracellular fluid volume regulation that in most cases results in accumulation of fluid, typically in the abdominal cavity (ascites) or lower extremities (edema). In approximately 5 to 10 percent of cirrhotic patients, fluid accumulates in the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Hepatic hydrothorax is defined as a pleural effusion, usually greater than 500 mL, in patients with cirrhosis and without primary cardiac, pulmonary, or pleural disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While patients with ascites can often tolerate up to 5 to 10 L of fluid with only mild symptoms, those with a pleural effusion can have severe symptoms (such as shortness of breath, cough, and hypoxemia) with as little as 1 to 2 L of fluid. This topic review will summarize issues related to hepatic hydrothorax while other complications of cirrhosis are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying mechanisms leading to fluid retention in patients with hepatic hydrothorax are similar to those leading to other forms of fluid accumulation in patients with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the exact mechanisms involved in the development of hepatic hydrothorax are incompletely understood, it probably results from the passage of ascites from the peritoneal to the pleural cavity through small diaphragmatic defects. These are typically less than 1 cm (and may be microscopic) and are generally located in the tendinous portion of the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/5-10\">",
"     5-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The negative intrathoracic pressure generated during inspiration favors the passage of fluid from the intra-abdominal to the pleural space. Thus, many patients have only mild or no clinically detectable ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/2,11-13\">",
"     2,11-13",
"    </a>",
"    ]. Hepatic hydrothorax develops when the absorptive capacity of the pleural space is exceeded. This theory is supported by studies using 99mTc-human albumin or 99mTc-sulphur colloid, which demonstrate unidirectional passage of these markers from the abdominal to the pleural cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/14-19\">",
"     14-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients usually present with shortness of breath, cough, hypoxemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. As noted above, ascites is not always present, although other features of cirrhosis may be apparent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common presentations include an acute tension hydrothorax with associated severe dyspnea and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/20\">",
"     20",
"    </a>",
"    ] or infection. Infection (referred to as \"spontaneous bacterial empyema\" [SBEM]) has been described in 13 to 16 percent of patients with hepatic hydrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. SBEM is defined as pleural fluid with a polymorphonuclear cell count &gt;500",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    or positive culture with exclusion of a parapneumonic effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. Fever and pleuritic chest pain can suggest the underlying cause, although localizing signs are not always present. Risk factors include low levels of pleural fluid C3, pleural fluid total protein, and a high Child-Pugh score [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality of SBEM is as high as 20 percent, even with anti-microbial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/21,22,24\">",
"     21,22,24",
"    </a>",
"    ]. Independent risk factors associated with poor outcome in SBEM are high MELD&ndash;Na score, initial ICU admission, and initial antibiotic treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/22\">",
"     22",
"    </a>",
"    ]. The etiologic agents in most cases are E. coli, Streptococcus species, Enterococcus, Klebsiella, or Pseudomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/25\">",
"     25",
"    </a>",
"    ]. Approximately one-half of episodes are associated with spontaneous bacterial peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a pleural effusion can usually be recognized on frontal chest radiograph, although small effusions may be visible only on the lateral view. Hepatic hydrothorax develops on the right side in approximately 85 percent of patients, while it is on the left side in approximately 13 percent and bilateral in approximately 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/12,26\">",
"     12,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A thoracentesis should be performed to confirm the diagnosis and to",
"    <strong>",
"     exclude",
"    </strong>",
"    alternate causes of a pleural effusion. Up to 20 percent of patients will have evidence of infection or a cause of pleural effusion other than hepatic hydrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic tests that should be performed include cell count, Gram stain and culture, serum and fluid protein, albumin, LDH, and bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1,2,12\">",
"     1,2,12",
"    </a>",
"    ]. Other tests on pleural fluid that may be useful depending upon the clinical suspicion include triglyceride level, pleural pH, adenosine deaminase and polymerase chain reaction (PCR) for mycobacterium, amylase, and cytology to exclude chylothorax, empyema, tuberculosis, pancreatitis, and malignancy, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural effusions deriving from portal hypertension are transudative in nature and therefore similar to the ascitic fluid, although some differences may be evident due to the different mechanisms of fluid absorption from the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. For instance, total protein and albumin may be slightly higher in hepatic hydrothorax, compared to levels in the ascitic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/9\">",
"     9",
"    </a>",
"    ]. The characteristics and the interpretation of pleural fluid in hepatic hydrothorax are described in the table (",
"    <a class=\"graphic graphic_table graphicRef52482 \" href=\"UTD.htm?14/39/14971\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In uncomplicated hepatic hydrothorax, the cell count is low (&lt;500 cells), and the total protein concentration is less than 2.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1\">",
"     1",
"    </a>",
"    ]. The measurement of the serum albumin-pleural gradient for determining a portal hypertension related cause has not been studied in hepatic hydrothorax. In our experience, the gradient is usually &gt;1.1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    similar to the high serum to ascites fluid albumin gradient classically present in patients with cirrhosis and ascites.",
"   </p>",
"   <p>",
"    The diagnostic criteria for spontaneous bacterial empyema (SBEM) are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive pleural fluid culture and a polymorphonuclear count &gt;250",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      Negative pleural fluid culture and a polymorphonuclear count &gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"     </li>",
"     <li>",
"      No evidence of pneumonia on a chest x-ray. Fluid should be inoculated directly into a blood culture bottle at the bedside. This increases the sensitivity for the diagnosis of SBEM from 33 to 77 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally recommend that patients also undergo a computed tomographic (CT) scan of the chest to exclude mediastinal, pulmonary, or pleural lesions. An abdominal ultrasound with Doppler study should be performed to examine the liver, rule out liver masses, ascertain the patency of the portal and hepatic veins and determine the presence of ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases where the diagnosis is uncertain, an intraperitoneal injection of 99mTc-sulphur colloid or 99mTc-human serum albumin can be helpful. With this test the radioisotopes migrate from the peritoneal cavity into the pleural space, therefore establishing a communication between both spaces and confirming the diagnosis of hepatic hydrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64287 \" href=\"UTD.htm?24/39/25204\">",
"     image 1",
"    </a>",
"    ). The optimal time to do an isotope study is shortly after therapeutic thoracentesis, when the fluid is reaccumulating in the pleural cavity. When the chest is maximally filled with fluid, there may be minimal transfer of the isotope across the diaphragm, resulting in a false-negative study. Failure of the marker to show up in the pleural space (when the study has been performed shortly after thoracentesis) indicates an alternate cause of the pleural effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important aspect of management is evaluation for liver transplantation (",
"    <a class=\"graphic graphic_algorithm graphicRef80148 \" href=\"UTD.htm?25/34/26158\">",
"     algorithm 1",
"    </a>",
"    ). The main goal of treatment is relief of symptoms and prevention of pulmonary complications and infections until liver transplantation can be performed, or palliative treatment in those who are not candidates for transplantation. The outcome of patients with hepatic hydrothorax undergoing liver transplantation is similar to that of patients who have liver transplantation due to other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are severely symptomatic should undergo a therapeutic thoracentesis followed by a sodium restricted diet and diuretics. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Thoracentesis'",
"    </a>",
"    below.) Less symptomatic patients can be treated initially with sodium restriction and diuretics. Options for patients who are refractory to sodium restriction and diuretics include serial thoracentesis, transjugular intrahepatic portosystemic shunt (TIPS) placement, pleurodesis, and thoracoscopic surgery.",
"   </p>",
"   <p>",
"    Chest tubes should",
"    <strong>",
"     not",
"    </strong>",
"    be placed. Placement of chest tubes in patients with hepatic hydrothorax can result in massive protein and electrolyte depletion, infection, renal failure, and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. A review of cases of from a tertiary care center over a ten-year period indicated that 16 out of 17 patients analyzed developed serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/32\">",
"     32",
"    </a>",
"    ]. These complications included acute kidney injury, pneumothorax, and empyema. Furthermore, once it has been inserted, it may be impossible to remove the tube because of the continuous reaccumulation of fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/31\">",
"     31",
"    </a>",
"    ]. Other complications include subcutaneous emphysema; lung, spleen, liver, and stomach lacerations, hemothorax resulting from intercostal artery laceration, unilateral pulmonary edema from rapid removal of fluid, and placement of the tube into the abdominal cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sodium restriction and diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hepatic hydrothorax is similar in principle to treatment of ascites. Patients who are actively consuming alcohol should be encouraged to abstain completely. Even if alcohol is not the only cause of their liver disease, (eg, in patients with cirrhosis due to chronic hepatitis C), the alcohol-related component of their liver disease may improve dramatically with abstinence.",
"   </p>",
"   <p>",
"    Education about the importance of dietary sodium restriction is also a central component of management. An 88 meq (2000 mg) per day sodium diet is the most practical and successful level of sodium restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. It can be followed in an outpatient setting without purchase of special types of food. Patients should also be instructed to avoid nonsteroidal antiinflammatory drugs (NSAIDs), which can cause sodium retention and renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=see_link\">",
"     \"NSAIDs: Electrolyte complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"     \"Patient information: Low sodium diet (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this diet will be effective alone only in the small subset of patients whose urinary sodium excretion is more than 78",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (88 meq intake minus 10 meq of nonurinary losses). Most patients will also require therapy with diuretics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Refractory hydrothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients have refractory hydrothorax. Patients with persistent hydrothorax despite diuretic therapy or those who develop diuretic-related complications are considered to have refractory hydrothorax. It is important to exclude noncompliance with dietary sodium restriction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diuretics. In addition to the history, measurement of 24-hour urinary sodium excretion can be helpful for determining compliance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial therapy of ascites in patients with cirrhosis\", section on 'Diuretic resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for patients who are considered to be truly refractory include repeated thoracentesis, transjugular intrahepatic portosystemic shunt placement, pleurodesis, and surgical repair of defects in the diaphragm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic thoracentesis is the most effective way of reducing large effusions (greater than 1.5 liters) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/1,2,12\">",
"     1,2,12",
"    </a>",
"    ]. After thoracentesis, diuretics should be started to prevent reaccumulation of fluid. As a general rule, no more than 2 L of fluid should be removed because of the risk of pulmonary edema and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/33\">",
"     33",
"    </a>",
"    ]. However, this \"2 L rule\" was developed in patients with causes of the effusion other than cirrhosis; patients with cirrhosis may be able to tolerate the removal of larger volumes of fluid. The amount of fluid can be estimated by chest radiograph or computed tomographic scan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of thoracentesis include pain at the puncture site, pneumothorax, hemothorax, vasovagal episodes, hemoptysis, air embolism, laceration of the liver or spleen, empyema, hemoptysis, and subcutaneous emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/34\">",
"     34",
"    </a>",
"    ]. The probability of complications increases in patients who require frequent therapeutic thoracentesis (such as every two to three weeks). The alternative approaches outlined below should be considered for these patients.",
"   </p>",
"   <p>",
"    Coagulopathy is not considered a contraindication to therapeutic thoracentesis. One study demonstrated no increased risk of bleeding in patients with prothrombin times up to twice the midpoint of the normal range, or platelet counts of more than",
"    <span class=\"nowrap\">",
"     50,000/microL;",
"    </span>",
"    the authors concluded that prophylactic transfusions are not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with a serum creatinine more than 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    had greater blood loss compared with those with lower values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Transjugular intrahepatic portosystemic shunt (TIPS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups have reported a beneficial effect of TIPS in patients with hepatic hydrothorax. Unfortunately, few of the studies described the rigor with which the refractoriness of the hydrothorax to medical therapy was determined. Despite this shortcoming, most series have demonstrated response rates in the range of 70 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/36-42\">",
"     36-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An illustrative study that reviewed the course after TIPS in 28 patients with hepatic hydrothorax revealed that the 30, 90, and 150-day mortality was 14, 25, and 53 percent, respectively. One-year survival without liver transplantation was 41 percent. In 68 percent of patients there was complete resolution of symptoms, and in 57 percent of cases there was disappearance of effusions on x-ray. TIPS was successful in 15 of 20 patients with a Child score &le;10 and in only one of eight patients with a Child score &gt;10. In the study, a Child score &ge;10 was a strong predictor of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the many potential risks of TIPS, we generally consider it in selected patients with a Child-Pugh score less than 10, who are younger than 70, and who do not have hepatic encephalopathy. Risk factors for mortality after TIPS placement for hepatic hydrothorax include a Child-Pugh score &lt;10, a pre-TIPS MELD score &gt;15, and an elevated pre-TIPS creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In addition, a lack of response in the hydrothorax after TIPS placement is associated with an increased mortality rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=see_link\">",
"     \"Indications for the use of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pleurodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis is commonly used to treat patients with recurrent, symptomatic pleural effusions due to malignancy. However, little information is available to guide the clinician in the management of recurrent, symptomatic, nonmalignant pleural effusions, even though both chemical pleurodesis and talc poudrage have been used in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical experience suggests that hepatic hydrothorax is the most difficult form of nonmalignant pleural effusion to treat with chemical pleurodesis. Because of the rapid migration of fluid from the abdomen into the pleural space, it is often difficult to keep the two pleural surfaces apposed long enough for the inflammatory process to result in pleural symphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, it is rarely performed and typically reserved for patients in whom no other options exist.",
"   </p>",
"   <p>",
"    In one of the largest series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    was performed in 18 patients with hepatic hydrothorax without repair of the diaphragmatic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/44\">",
"     44",
"    </a>",
"    ]. After three months, 44 percent of cases recurred. In addition, there were several complications including fever, chest pain, empyema, incomplete reexpansion, pneumonia, and wound infection. Overall morbidity was 57 percent while mortality was 39 percent during follow-up.",
"   </p>",
"   <p>",
"    Another study included 15 patients with refractory hepatic hydrothorax who underwent video assisted thoracoscopic surgery with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/45\">",
"     45",
"    </a>",
"    ]. Control of symptoms and resolution of effusion was achieved in 11 (73 percent), with most patients remaining asymptomatic for a follow up period of five months. Complications included pain around the chest tube site, low-grade fever with leukocytosis, pleurocutaneous fistula, and empyema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"     \"An overview of medical thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A series of five patients underwent combined thorascopically-guided mechanical and chemical pleurodesis aided by placement of an intraperitoneal drain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/46\">",
"     46",
"    </a>",
"    ]. The drain was intended to prevent reaccumulation of ascites while the inflammation and adhesion formation progressed. The procedure successfully prevented recurrence of hydrothorax in four patients and decreased the need for thoracentesis in the fifth patient. There were no deaths attributable to the procedure, but infections of the pleural fluid were observed in four patients. Four patients required hospitalization for three or more weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Thoracoscopic repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diaphragmatic repair involving a pleural flap and surgical mesh reinforcement has been described but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous bacterial empyema has been described in 13 to 16 percent of patients with hepatic hydrothorax. Therapy with an intravenous third generation cephalosporin antibiotic (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 to 2 gm every 24 hours for 7 to 10 days) should be started after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/21\">",
"     21",
"    </a>",
"    ]. In patients in whom there is slow clinical recovery, a repeat thoracentesis is useful to document that the patient is responding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splanchnic vasoconstrictor drugs can improve underlying hemodynamic derangements that lead to extracellular fluid accumulation formation in cirrhosis, cause increased natriuresis, and theoretically improve the action of diuretics in order to maximize fluid mobilization. A case report described successful treatment of a patient with a refractory hepatic hydrothorax despite a TIPS and pleurodesis who was treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (at a dose of 25",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    on the first day, 50",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    on the second day, and then 100",
"    <span class=\"nowrap\">",
"     mcg/hour",
"    </span>",
"    for five more days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/48\">",
"     48",
"    </a>",
"    ]. Another report described successful treatment of hepatic hydrothorax in a patient with concomitant hepatorenal syndrome after the administration of terlipressin (1 mg IV bolus injection every six hours along with intravenous albumin infusion of 40",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30263/abstract/49\">",
"     49",
"    </a>",
"    ]. It is unclear whether these approaches can lead to a sustained benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic hydrothorax should be suspected in all patients with cirrhosis or portal hypertension and an undiagnosed pleural effusion, regardless of the presence of ascites.",
"     </li>",
"     <li>",
"      Diagnostic thoracentesis should be performed to exclude alternative etiologies, especially infection. Computed tomography may be useful in assessing any underlying pleural or pulmonary disease.",
"     </li>",
"     <li>",
"      Treatments for hepatic hydrothorax include liver transplantation, dietary changes, diuretics, thoracentesis, and transjugular intrahepatic portosystemic shunt (TIPS) (",
"      <a class=\"graphic graphic_algorithm graphicRef80148 \" href=\"UTD.htm?25/34/26158\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with confirmed hepatic hydrothorax should be referred for liver transplantation if they are otherwise suitable candidates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"       \"Patient selection for liver transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that all patients be counseled on avoidance of alcohol and NSAIDs, a low sodium diet, and receive appropriate doses of diuretics (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"       \"Initial therapy of ascites in patients with cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest a therapeutic thoracentesis be performed in patients who are severely symptomatic and in those who do not tolerate diuretics (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest transjugular intrahepatic portosystemic shunt (TIPS) in patients who require repeated thoracentesis, provided that they are selected carefully (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally suggest TIPS for patients with a Child-Pugh score less than 10, who are younger than 70, and who do not have hepatic encephalopathy. The Model for End-stage Liver Disease (MELD) score can also be helpful for guiding patient selection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link&amp;anchor=H9#H9\">",
"       \"Model for End-stage Liver Disease (MELD)\", section on 'Use of MELD for selecting patients for TIPS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest pleurodesis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      repair of the diaphragm in patients who are not eligible for TIPS and in whom more conservative measures have been unsuccessful (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend against placement of a chest tube since can be associated with severe complications (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/1\">",
"      Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/2\">",
"      Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/3\">",
"      Xiol X, Guardiola J. Hepatic hydrothorax. Curr Opin Pulm Med 1998; 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/4\">",
"      Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med 2003; 9:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/5\">",
"      Huang PM, Chang YL, Yang CY, Lee YC. The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding. J Thorac Cardiovasc Surg 2005; 130:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/6\">",
"      Lieberman FL, Hidemura R, Peters RL, Reynolds TB. Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med 1966; 64:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/7\">",
"      EMERSON PA, DAVIES JH. Hydrothorax complicating ascites. Lancet 1955; 268:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/8\">",
"      Mouroux J, Perrin C, Venissac N, et al. Management of pleural effusion of cirrhotic origin. Chest 1996; 109:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/9\">",
"      Chen A, Ho YS, Tu YC, et al. Diaphragmatic defect as a cause of massive hydrothorax in cirrhosis of liver. J Clin Gastroenterol 1988; 10:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/10\">",
"      Zenda T, Miyamoto S, Murata S, Mabuchi H. Detection of diaphragmatic defect as the cause of severe hepatic hydrothorax with magnetic resonance imaging. Am J Gastroenterol 1998; 93:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/11\">",
"      C&aacute;rdenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 2003; 17:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/12\">",
"      Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999; 107:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/13\">",
"      Serrat J, Roza JJ, Planella T. Hepatic hydrothorax in the absence of ascites: respiratory failure in a cirrhotic patient. Anesth Analg 2004; 99:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/14\">",
"      Rubinstein D, McInnes IE, Dudley FJ. Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology 1985; 88:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/15\">",
"      Benet A, Vidal F, Toda R, et al. Diagnosis of hepatic hydrothorax in the absence of ascites by intraperitoneal injection of 99m-Tc-Fluor colloid. Postgrad Med J 1992; 68:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/16\">",
"      Serena A, Aliaga L, Richter JA, et al. Scintigraphic demonstration of a diaphragmatic defect as the cause of massive hydrothorax in cirrhosis. Eur J Nucl Med 1985; 11:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/17\">",
"      Kakizaki S, Katakai K, Yoshinaga T, et al. Hepatic hydrothorax in the absence of ascites. Liver 1998; 18:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/18\">",
"      Mente�� BB, Kayhan B, G&ouml;rg&uuml;l A, Unal S. Hepatic hydrothorax in the absence of ascites: report of two cases and review of the mechanism. Dig Dis Sci 1997; 42:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/19\">",
"      Giacobbe A, Facciorusso D, Tonti P, et al. Hydrothorax complicating cirrhosis in the absence of ascites. J Clin Gastroenterol 1993; 17:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/20\">",
"      Castellote J, Gornals J, Lopez C, Xiol X. Acute tension hydrothorax: a life-threatening complication of cirrhosis. J Clin Gastroenterol 2002; 34:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/21\">",
"      Xiol X, Castellv&iacute; JM, Guardiola J, et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology 1996; 23:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/22\">",
"      Chen CH, Shih CM, Chou JW, et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int 2011; 31:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/23\">",
"      Sese E, Xiol X, Castellote J, et al. Low complement levels and opsonic activity in hepatic hydrothorax: its relationship with spontaneous bacterial empyema. J Clin Gastroenterol 2003; 36:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/24\">",
"      Garcia N Jr, Mihas AA. Hepatic hydrothorax: pathophysiology, diagnosis, and management. J Clin Gastroenterol 2004; 38:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/25\">",
"      Falchuk KR, Jacoby I, Colucci WS, Rybak ME. Tetracycline-induced pleural symphysis for recurrent hydrothorax complicating cirrhosis. A new approach to treatment. Gastroenterology 1977; 72:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/26\">",
"      Alagiakrishnan K, Patel PJ. Left-sided hepatic hydrothorax with ascites. Int J Clin Pract 1999; 53:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/27\">",
"      Xiol X, Castellote J, Cortes-Beut R, et al. Usefulness and complications of thoracentesis in cirrhotic patients. Am J Med 2001; 111:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/28\">",
"      Xiol X, Tremosa G, Castellote J, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005; 18:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/29\">",
"      Borchardt J, Smirnov A, Metchnik L, Malnick S. Treating hepatic hydrothorax. BMJ 2003; 326:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/30\">",
"      Runyon BA, Greenblatt M, Ming RH. Hepatic hydrothorax is a relative contraindication to chest tube insertion. Am J Gastroenterol 1986; 81:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/31\">",
"      Liu LU, Haddadin HA, Bodian CA, et al. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004; 126:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/32\">",
"      Orman ES, Lok AS. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int 2009; 3:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/33\">",
"      Sherman SC. Reexpansion pulmonary edema: a case report and review of the current literature. J Emerg Med 2003; 24:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/34\">",
"      Collins TR, Sahn SA. Thoracocentesis. Clinical value, complications, technical problems, and patient experience. Chest 1987; 91:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/35\">",
"      McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/36\">",
"      Gordon FD, Anastopoulos HT, Crenshaw W, et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997; 25:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/37\">",
"      Strauss RM, Martin LG, Kaufman SL, Boyer TD. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 1994; 89:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/38\">",
"      Siegerstetter V, Deibert P, Ochs A, et al. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/39\">",
"      Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/40\">",
"      Conklin LD, Estrera AL, Weiner MA, et al. Transjugular intrahepatic portosystemic shunt for recurrent hepatic hydrothorax. Ann Thorac Surg 2000; 69:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/41\">",
"      R&ouml;ssle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/42\">",
"      Dhanasekaran R, West JK, Gonzales PC, et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol 2010; 105:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/43\">",
"      Wilputte JY, Goffette P, Zech F, et al. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg 2007; 70:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/44\">",
"      Milanez de Campos JR, Filho LO, de Campos Werebe E, et al. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000; 118:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/45\">",
"      Ferrante D, Arguedas MR, Cerfolio RJ, et al. Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax. Am J Gastroenterol 2002; 97:3172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/46\">",
"      Northup PG, Harmon RC, Pruett TL, et al. Mechanical pleurodesis aided by peritoneal drainage: procedure for hepatic hydrothorax. Ann Thorac Surg 2009; 87:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/47\">",
"      Huang PM, Kuo SW, Lee JM. Thoracoscopic diaphragmatic repair for refractory hepatic hydrothorax: application of pleural flap and mesh onlay reinforcement. Thorac Cardiovasc Surg 2006; 54:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/48\">",
"      Barreales M, S&aacute;enz-L&oacute;pez S, Igarzabal A, et al. Refractory hepatic hydrothorax: successful treatment with octreotide. Rev Esp Enferm Dig 2005; 97:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30263/abstract/49\">",
"      Ibrisim D, Cakaloglu Y, Akyuz F, et al. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol 2006; 41:862.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1242 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30263=[""].join("\n");
var outline_f29_35_30263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sodium restriction and diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Refractory hydrothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Transjugular intrahepatic portosystemic shunt (TIPS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Thoracoscopic repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other treatment options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1242|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/34/26158\" title=\"algorithm 1\">",
"      Approach hepatic hydrothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1242|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/39/25204\" title=\"diagnostic image 1\">",
"      Hepatic hydrothorax nuclear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1242|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/39/14971\" title=\"table 1\">",
"      Hepatic hydrothorax features",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34359?source=related_link\">",
"      Indications for the use of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/57/38803?source=related_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_35_30264="What's new in obstetrics and gynecology";
var content_f29_35_30264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in obstetrics and gynecology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30264/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30264/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30264/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/35/30264/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OBSTETRICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Adverse pregnancy and birth outcomes in women with bipolar disorder",
"    </span>",
"   </p>",
"   <p>",
"    Adverse pregnancy and birth outcomes may occur more often in women with bipolar disorder&nbsp;compared&nbsp;with women without the disease, and the use of mood stabilizers does not appear to impact most outcomes. A retrospective study of national registries&nbsp;evaluated outcomes in over&nbsp;800&nbsp;pregnant women with bipolar disorder who were either treated with mood stabilizers (antipsychotics, carbamazepine, lamotrigine, lithium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    valproate) or not, and in&nbsp;over 330,000 pregnant women without bipolar disorder&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Induced or planned caesarean delivery&nbsp;and preterm birth occurred in more women with bipolar disorder, regardless of treatment status. However, an increase in rates of microcephaly and neonatal hypoglycemia was seen only in patients with untreated bipolar disorder.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=see_link&amp;anchor=H6188640#H6188640\">",
"     \"Bipolar disorder in women: Contraception and preconception assessment and counseling\", section on 'Risk of adverse pregnancy and birth outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis in obese women undergoing cesarean delivery",
"    </span>",
"   </p>",
"   <p>",
"    The dosing&nbsp;of cephalosporins for&nbsp;obese women undergoing cesarean delivery has been clarified in guidelines developed jointly by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Surgical Infection Society, and the Society for Healthcare Epidemiology of America [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/2\">",
"     2",
"    </a>",
"    ]. The recommended dose of cefazolin is 2 grams for women &lt;120 kg and 3 grams for those &ge;120 kg.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=see_link&amp;anchor=H6#H6\">",
"     \"Cesarean delivery of the obese woman\", section on 'Surgical-site infection prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapy for perinatal depression",
"    </span>",
"   </p>",
"   <p>",
"    Cognitive-behavioral therapy (CBT) can be useful in pregnant and postpartum patients.&nbsp;This was demonstrated in&nbsp;a 16-week randomized trial in which&nbsp;CBT (12 individual sessions, each lasting 50 minutes) was compared with standard care (feedback about depression status, educational material about perinatal depression, and referrals for psychotherapy) in 55 low-income, perinatal outpatients with unipolar major depression who were attending obstetric clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/3\">",
"     3",
"    </a>",
"    ]. CBT&nbsp;included efforts to increase adherence, such as telephone calls, letters, and home visits by therapists. Improvement was greater with CBT than standard care, and treatment gains persisted at the three-month follow-up assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H13804399#H13804399\">",
"     \"Depression in pregnant women: Management\", section on 'Cognitive-behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management of asymptomatic neonates exposed to HSV during delivery",
"    </span>",
"   </p>",
"   <p>",
"    The risk of herpes simplex virus (HSV)&nbsp;transmission to neonates&nbsp;during delivery in women with active genital HSV lesions varies from &lt;2 percent for recurrent maternal&nbsp;infection to 25 to 60 percent for primary infection. The increasing availability of HSV serologic tests that distinguish between HSV-1 and HSV-2 permits more accurate characterization of maternal infection (",
"    <a class=\"graphic graphic_table graphicRef80693 \" href=\"UTD.htm?9/63/10235\">",
"     table 1",
"    </a>",
"    ), allowing the evaluation and management of asymptomatic neonates exposed to HSV at delivery to be tailored according to risk. In February 2013 the American Academy of Pediatrics published guidelines for the management of asymptomatic neonates born to women with active genital lesions&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/4\">",
"     4",
"    </a>",
"    ].&nbsp;The guidelines recommend that women with active genital lesions at the time of delivery and no history of HSV undergo type-specific HSV serologic testing after delivery (if available). Asymptomatic neonates born to such women should undergo full evaluation for HSV at approximately 24 hours of age and be treated with acyclovir 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously per day divided in three doses. The duration of therapy is determined by the neonate&rsquo;s clinical status, results of the neonate&rsquo;s evaluation for HSV disease, and maternal HSV infection classification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link&amp;anchor=H510233446#H510233446\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\", section on 'No maternal history of HSV, active lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Three-dose intermittent preventive treatment of malaria during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The previous recommendation for delivering Intermittent Preventive Treatment (IPTp) for malaria to pregnant women in areas of medium and high malaria transmission was a two-dose regimen. In a systematic review and meta-analysis, use of an IPTp&nbsp;regimen that&nbsp;included three or more doses,&nbsp;rather than&nbsp;a&nbsp;two-dose regimen, resulted in fewer low birth weight infants, less placental malaria, and less moderate to severe maternal anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, for pregnant women who reside in areas of medium and high malaria transmission, we recommend treatment with three doses of sulfadoxine pyrimethamine as Intermittent Preventive Treatment (IPTp), rather than two doses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prevention of malaria in pregnancy\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Use of selective serotonin reuptake inhibitors (SSRIs) to treat pregnant patients does not appear to be associated with stillbirth or infant mortality. In an observational study of over one million pregnancies, registries from five countries were examined for information about prescriptions, maternal characteristics, pregnancy outcomes, and neonatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/6\">",
"     6",
"    </a>",
"    ]. More than 29,000 women had filled a prescription for an SSRI. After accounting for maternal age, smoking, diabetes, hypertension, and hospitalization for psychiatric illness, the risks of stillbirth and infant mortality were comparable for women who used or did not use SSRIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H8#H8\">",
"     \"Depression in pregnant women: Management\", section on 'Pregnancy complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tdap during pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Infants younger than three months of age are at highest risk of morbidity and mortality from this infection, and many infants contract pertussis from their mothers. Vaccination of the mother can thus significantly decrease the risk of infant exposure, and placental transfer of maternal antibodies may additionally provide a degree of passive protection to the infant for two to six months. In 2013, the United States Advisory Committee on Immunization Practices (ACIP) recommended that all pregnant women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during",
"    <strong>",
"     each",
"    </strong>",
"    pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to increase the likelihood of optimal protection against pertussis for both the mother and her infant during the first few months of the infant&rsquo;s life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/7\">",
"     7",
"    </a>",
"    ]. Previously, Tdap was recommended only for pregnant women who had not previously received the acellular pertussis vaccine during adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vertical transmission of hepatitis C",
"    </span>",
"   </p>",
"   <p>",
"    A systematic review of observational studies on risk of mother-to-infant hepatitis C virus (HCV) transmission found no clear association between infection in the infant and mode of delivery or breastfeeding practices [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/8\">",
"     8",
"    </a>",
"    ]. Women infected with HCV",
"    <strong>",
"     do not",
"    </strong>",
"    need to be advised to avoid vaginal delivery or breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link&amp;anchor=H68345961#H68345961\">",
"     \"Vertical transmission of hepatitis C virus\", section on 'Mode of delivery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link&amp;anchor=H68346108#H68346108\">",
"     \"Vertical transmission of hepatitis C virus\", section on 'Breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Safety and efficacy of influenza vaccination in pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Influenza vaccination is recommended for pregnant women because both mother and fetus are at increased risk of complications related to this infection, including fetal death. In addition, maternal vaccination provides passive protection to the infant. However, concerns about vaccine safety have interfered with compliance in this patient group. The safety and efficacy of vaccination of pregnant women were confirmed in a retrospective analysis of over 100,000 pregnancies during the 2009 influenza A (H1N1) pandemic in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/9\">",
"     9",
"    </a>",
"    ]. Vaccination during pregnancy substantially reduced the risk of a maternal influenza diagnosis (adjusted hazard ratio, 0.30) and was associated with a trend in reduction of fetal death. All women who are pregnant or will be pregnant during influenza season should receive the inactivated influenza vaccine, regardless of pregnancy trimester. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795661#H5795661\">",
"     \"Influenza and pregnancy\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     New guidelines for umbilical cord clamping",
"    </span>",
"   </p>",
"   <p>",
"    The optimal timing of clamping of the umbilical cord during delivery has been an area of some debate. A December 2012 American College of Obstetricians and Gynecologists (ACOG) committee opinion concluded that the decision to perform early versus delayed cord clamping in term deliveries should be based on patient-specific factors, particularly the infant&rsquo;s risk of developing iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/10\">",
"     10",
"    </a>",
"    ]. For preterm deliveries, they recommended delayed cord clamping given the significant reduction in intraventricular hemorrhage associated with this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of normal labor and delivery\", section on 'Cord clamping'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     New definitions for failed induction and labor arrest",
"    </span>",
"   </p>",
"   <p>",
"    In an effort to reduce unnecessary cesarean deliveries for failed induction and failure to progress, a workshop convened by the United States National Institute of Child Health and Human Development (NICHD), Society of Maternal-Fetal Medicine (SMFM), and ACOG proposed new criteria for failed induction and arrest of labor in the first and second stages [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/12\">",
"     12",
"    </a>",
"    ]. The proposed criteria were based upon contemporary data on the normal progress of labor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H30#H30\">",
"     \"Principles of labor induction\", section on 'Failed induction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link&amp;anchor=H8#H8\">",
"     \"Abnormal labor: Protraction and arrest disorders\", section on 'Diagnosis of labor abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy of tocolysis for preterm labor",
"    </span>",
"   </p>",
"   <p>",
"    In a systematic review and network meta-analysis of 95 randomized trials of tocolytic therapy for preterm labor, all of the commonly used tocolytic drugs were statistically more effective than",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    therapy for delaying delivery for 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/13\">",
"     13",
"    </a>",
"    ]. Prostaglandin inhibitors and calcium channel blockers had the highest probability of delaying delivery and improving neonatal and maternal outcomes. This analysis provides additional evidence to support current clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link&amp;anchor=H1277601#H1277601\">",
"     \"Inhibition of acute preterm labor\", section on 'Approach to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     New guideline for DNA-based aneuploidy screening",
"    </span>",
"   </p>",
"   <p>",
"    Examination of cell free fetal DNA from the plasma of pregnant women has high sensitivity and specificity for detection of trisomy 21, 13, and 18, but the role of this test in screening for these abnormalities is unclear. In December 2012, a Committee Opinion from the American College of Obstetricians and Gynecologists (ACOG) suggested offering this test as a primary screening approach for women with singleton gestations at increased risk of fetal aneuploidy and as a secondary screening test to women with a screen-positive result on maternal analyte testing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/14\">",
"     14",
"    </a>",
"    ]. ACOG advised against its use in women at low risk of fetal aneuploidy and those with a multiple gestation or a structural fetal anomaly on ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H486544#H486544\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Cell-free free fetal DNA in maternal blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OFFICE GYNECOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ospemifene for treatment of vulvovaginal atrophy",
"    </span>",
"   </p>",
"   <p>",
"    Ospemifene is&nbsp;the first&nbsp;selective estrogen receptor modulator that is effective in treating dyspareunia resulting from menopausal vulvovaginal atrophy. It&nbsp;is an&nbsp;oral medication and&nbsp;may be helpful for women with symptomatic atrophy that is not relieved with vaginal moisturizers or lubricants and who cannot (severe arthritis, obesity, vulvodynia) or prefer not to use a vaginal product. In a&nbsp;randomized trial,&nbsp;12 weeks of ospemifene was significantly more effective than placebo in improving dyspareunia, although the benefit beyond that of placebo was modest [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/15\">",
"     15",
"    </a>",
"    ]. Ospemifene&nbsp;has been approved by the US Food and Drug Administration, but further study is needed to compare it to vaginal estrogen therapy and to&nbsp;evaluate the risk of long-term adverse effects. It is anticipated to be available for clinical use in June 2013. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link&amp;anchor=H2475847#H2475847\">",
"     \"Treatment of vaginal atrophy\", section on 'Selective estrogen receptor modulators'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=see_link\">",
"     \"Ospemifene: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Long-term use of postmenopausal hormone therapy",
"    </span>",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) has published an updated meta-analysis of postmenopausal hormone therapy (nine trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/16\">",
"     16",
"    </a>",
"    ]. Results were largely based upon the two Women's Health Initiative trials, and the mean age of subjects was &gt;60 years. Estrogen plus progestin, as well as&nbsp;unopposed estrogen, decreased fracture risk but increased&nbsp;the risk for stroke, venous thromboembolic events, and gallbladder disease. Estrogen plus progestin increased risk for breast cancer, but unopposed estrogen decreased breast cancer risk. Based upon these data, the USPSTF continues to recommend against the use of both combined estrogen and progestin and unopposed estrogen for prevention of chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, they note that this recommendation does not apply to women considering&nbsp;hormone therapy for relief of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H91121219#H91121219\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     New levonorgestrel-releasing IUD",
"    </span>",
"   </p>",
"   <p>",
"    A lower-dose (13.5 mg) levonorgestrel-releasing intrauterine device (IUD; Skyla) became available in the United States in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/19\">",
"     19",
"    </a>",
"    ]. It is smaller in size than the 52 mg levonorgestrel IUD (Mirena)&nbsp;and thus may be easier to insert in nulliparous women. Because of the lower levonorgestrel dose, it is approved for up to three years of use (the 52 mg dose is approved for up to five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     \"Levonorgestrel: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Levonorgestrel intrauterine device for menorrhagia",
"    </span>",
"   </p>",
"   <p>",
"    The levonorgestrel intrauterine device (LNG-IUD) is an effective treatment for menorrhagia. Quality of life outcomes were evaluated for the first time in a randomized trial that assigned women to the LNG-IUD (Mirena) or treatment with other medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/21\">",
"     21",
"    </a>",
"    ]. Women in the LNG-IUD group had significantly higher scores in six domains of daily life at six months and two years. Significantly more women in the LNG-IUD group continued treatment at two years (64 versus 38 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H19#H19\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Levonorgestrel-IUD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Progestin therapy for endometrial hyperplasia",
"    </span>",
"   </p>",
"   <p>",
"    Progestin therapy has been found to be an effective treatment for complex atypical hyperplasia, particularly for women who wish to preserve fertility. A meta-analysis of 14 studies of women with complex atypical hyperplasia reported a regression rate of 86 percent, relapse rate of 26 percent, and live birth rate of 26 percent; median follow-up was 11 to 77 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37943?source=see_link&amp;anchor=H510607#H510607\">",
"     \"Management of endometrial hyperplasia\", section on 'Progestin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cryopreservation of mature oocytes",
"    </span>",
"   </p>",
"   <p>",
"    Cryopreservation of mature oocytes is no longer considered an experimental procedure. In January 2013, the Practice Committees of the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) concluded that mature oocyte cryopreservation is a reasonable option for preservation of fertility when medically indicated and embryo cryopreservation is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H5#H5\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Oocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GYNECOLOGIC SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Robotic versus conventional laparoscopic hysterectomy",
"    </span>",
"   </p>",
"   <p>",
"    Robot-assisted laparoscopic hysterectomy is more costly than conventional laparoscopic surgery and outcomes appear comparable to conventional laparoscopic or vaginal hysterectomy. This was&nbsp;illustrated in a prospective cohort study of over 260,000 women who underwent hysterectomy for benign indications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/24\">",
"     24",
"    </a>",
"    ]. Robotic and conventional laparoscopic approaches had similar rates of complications (5.5 versus 5.3 percent). While the robotic approach was associated with a decrease in hospital stays of &gt;2 days (19.6 versus 24.9 percent), the cost was an additional $2189 per case. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link&amp;anchor=H24766120#H24766120\">",
"     \"Laparoscopic approach to hysterectomy\", section on 'Robot-assisted laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hysteroscopic metroplasty outcomes",
"    </span>",
"   </p>",
"   <p>",
"    A congenital uterine septum can result in infertility or recurrent miscarriage. A meta-analysis of 29 observational studies evaluated hysteroscopic metroplasty for&nbsp;uterine septum removal&nbsp;in women who desired pregnancy and were not treated with in vitro fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/25\">",
"     25",
"    </a>",
"    ]. After the procedure, the pregnancy rate&nbsp;was 64 percent and the&nbsp;live birth rate&nbsp;was 54 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29014?source=see_link&amp;anchor=H6324043#H6324043\">",
"     \"Surgical management of congenital uterine anomalies\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Serum progesterone and ectopic pregnancy",
"    </span>",
"   </p>",
"   <p>",
"    Serum progesterone concentrations are higher in viable intrauterine pregnancies than in ectopic pregnancies and intrauterine pregnancies that are destined to abort. A meta-analysis of cohort studies of women in the first trimester of pregnancy evaluated use of a single measurement of serum progesterone for the diagnosis of a nonviable pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/26\">",
"     26",
"    </a>",
"    ]. For women with bleeding or pain and an inconclusive pelvic ultrasound, a progesterone &lt;3.2 to 6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (10.2 to 19.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    had a sensitivity of 75 percent and a specificity of 98 percent. Serum progesterone testing is not used routinely for the evaluation of ectopic pregnancy, since in some clinical contexts it does not provide information in addition to the results of serum human chorionic gonadotropic testing and pelvic ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'Progesterone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     GYNECOLOGIC ONCOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     PET/CT scan in the work-up of suspected recurrent endometrial cancer",
"    </span>",
"   </p>",
"   <p>",
"    Although surveillance imaging is not used for asymptomatic women after treatment for endometrial cancer, imaging should be performed for patients who are symptomatic or have abnormal findings on physical examination. For women suspected of having recurrent disease, positron emissions tomography (PET) scan is a reasonable imaging study. This is supported by a&nbsp;2013 meta-analysis that showed PET (particularly when performed with computerized tomography) had excellent sensitivity and specificity in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/27\">",
"     27",
"    </a>",
"    ].&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H1048815#H1048815\">",
"     \"Overview of endometrial carcinoma\", section on 'Surveillance protocols'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Ovarian cancer risk, parity, and infertility treatment",
"    </span>",
"   </p>",
"   <p>",
"    Parous&nbsp;women appear to have a decreased risk of ovarian cancer.&nbsp;A retrospective cohort study of over 20,000 women who were seeking treatment for infertility&nbsp;found that the risk of ovarian cancer in parous women was approximately one-half the risk in nulliparous&nbsp;women&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/28\">",
"     28",
"    </a>",
"    ]. Additionally, the study&nbsp;found&nbsp;no increase in the rate of ovarian cancer for parous women who underwent in vitro fertilization.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092166#H6092166\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Nulliparity and other obstetric factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"    </span>",
"   </p>",
"   <p>",
"    In the largest cohort study of high-risk women, the United Kingdom Familial Ovarian Cancer Screen Study (UK FOCSS), 3563 women with a familial ovarian cancer syndrome (estimated minimum lifetime risk of 10 percent) who had declined or deferred risk reducing salpingo-oophorectomy (RRSO) were screened annually for a mean of 3.2 years with a combination of transvaginal ultrasound and CA-125 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/29\">",
"     29",
"    </a>",
"    ]. Sensitivity for the detection of incident ovarian",
"    <span class=\"nowrap\">",
"     cancer/fallopian",
"    </span>",
"    tube cancer was 81.0 to 87.5 percent. The positive predictive value of incident screening was 25.5 percent, which exceeds the threshold of 10 percent considered necessary for ovarian cancer screening. 30.8 percent (4 of 13) of incident cancers were stage I or II.&nbsp;",
"    <br/>",
"    <br/>",
"    Although&nbsp;RRSO&nbsp;remains the only reliable method of decreasing mortality from ovarian cancer in this high-risk population, this study suggests that screening&nbsp;has the potential to somewhat reduce risk for women who wish to maintain their childbearing potential until they are ready to undergo surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for ovarian cancer\", section on 'High-risk women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Hormone receptor expression and prognosis in ovarian cancer",
"    </span>",
"   </p>",
"   <p>",
"    Hormone receptor expression is a prognostic factor in breast cancer, but whether it is a prognostic factor in ovarian cancer is unclear. The results of a 2013&nbsp;meta-analysis indicate that while high progesterone receptor expression is associated with improved overall&nbsp;survival in patients with ovarian cancer, estrogen receptor expression is not [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/30\">",
"     30",
"    </a>",
"    ]. The relevance of these findings&nbsp;to treatment requires further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H6099435#H6099435\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Chemotherapy plus bevacizumab for recurrent, advanced, or metastatic cervical cancer",
"    </span>",
"   </p>",
"   <p>",
"    Women with recurrent, metastatic, or advanced cervical cancer should receive treatment consisting of a platinum-based combination chemotherapy plus the angiogenesis inhibitor bevacizumab. This recommendation is based on the results of the GOG 240 study, in which over 400 women with stage IVB recurrent or persistent cervical squamous cell cancer or adenocarcinoma were randomly assigned to chemotherapy (paclitaxel plus either&nbsp;cisplatin or topotecan) with or without bevacizumab. Although the final data have yet to be reported, results from the second interim analysis showed the addition of bevacizumab to chemotherapy improved overall survival by four months compared to chemotherapy alone (17 versus 13 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    While we await the final analysis of GOG 240 to better evaluate the toxicity profile of treatment and whether the specific chemotherapy regimen had an impact on survival, bevacizumab should be incorporated into the first-line treatment of metastatic or recurrent cervical cancer. Although the preferred chemotherapy combination to use with bevacizumab has not been established, the choice of chemotherapy should mirror the approach to selection of agents for patients who do not receive bevacizumab. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=see_link&amp;anchor=H2177909474#H2177909474\">",
"     \"Management of recurrent or metastatic cervical cancer\", section on 'First-line treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Intraoperative myometrial inspection for endometrial cancer",
"    </span>",
"   </p>",
"   <p>",
"    Surgical staging for endometrial cancer includes gross inspection of the uterine specimen. Invasion of &gt;50 percent of the thickness of the myometrium is associated with lymph node metastases and may impact whether lymphadenectomy is performed. A meta-analysis of 16 studies including 2567 women with endometrial cancer evaluated the diagnostic performance of intraoperative gross inspection to detect &gt;50 percent invasion compared to estimates from final histology and found a sensitivity of 75 percent and a specificity of 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H8#H8\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Intraoperative gross inspection and frozen section'",
"    </a>",
"    .)&nbsp;&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Duration of adjuvant tamoxifen for breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    For women taking tamoxifen as adjuvant therapy for breast cancer, the usual recommendation is for a five year course of therapy. However, the results of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial found that women who took tamoxifen for ten years had a significantly lower risk of recurrence and mortality compared to women who took tamoxifen for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/33\">",
"     33",
"    </a>",
"    ]. A longer course of tamoxifen, however, also resulted in a significantly higher incidence of adverse events including endometrial cancer, pulmonary embolus, and ischemic heart disease. Overall, these results support the use of tamoxifen for ten years in women who are tolerating treatment rather than five years. This is particularly true for patients with a relatively higher risk of recurrence based on their tumor characteristics (ie, pathological node involvement, large tumor size, or high tumor grade). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     UROGYNECOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Sling release after midurethral sling procedures",
"    </span>",
"   </p>",
"   <p>",
"    Voiding dysfunction or mesh erosion following a midurethral sling procedure requires sling release (transection of the sling) in some women. In a retrospective study of over 180,000 women, the cumulative rate of sling release performed at nine years postoperatively was 1.3 percent for the indication of urinary retention and 2.5 percent for mesh erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link&amp;anchor=H4702658#H4702658\">",
"     \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Sling release'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link&amp;anchor=H3907598#H3907598\">",
"     \"Stress urinary incontinence in women: Retropubic midurethral slings\", section on 'Vaginal mesh erosion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Antenatal prophylactic pelvic floor muscle exercises",
"    </span>",
"   </p>",
"   <p>",
"    Pelvic floor muscle exercises (PFME) performed during pregnancy help to decrease the short-term risk of urinary incontinence in women without prior incontinence, but a long-term benefit has not been established. This was illustrated in a meta-analysis of randomized trials that found that continent, mostly nulliparous, women who were assigned to perform antenatal PFME compared with those who were not had a significantly decreased risk of urinary incontinence at three to six months postpartum (18 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30264/abstract/35\">",
"     35",
"    </a>",
"    ]. No significant effect of PFME on incontinence was seen at six or more months postpartum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link&amp;anchor=H13#H13\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\", section on 'Prophylactic pelvic floor muscle exercises'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/1\">",
"      Bod&eacute;n R, Lundgren M, Brandt L, et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 2012; 345:e7085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/2\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/3\">",
"      O'Mahen H, Himle JA, Fedock G, et al. A PILOT RANDOMIZED CONTROLLED TRIAL OF COGNITIVE BEHAVIORAL THERAPY FOR PERINATAL DEPRESSION ADAPTED FOR WOMEN WITH LOW INCOMES. Depress Anxiety 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/4\">",
"      Kimberlin DW, Baley J, Committee on infectious diseases, Committee on fetus and newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013; 131:e635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/5\">",
"      Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA 2013; 309:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/6\">",
"      Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309:48.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/8\">",
"      Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/9\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/10\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. Committee Opinion No.543: Timing of umbilical cord clamping after birth. Obstet Gynecol 2012; 120:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/11\">",
"      Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev 2012; 8:CD003248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/12\">",
"      Spong CY, Berghella V, Wenstrom KD, et al. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol 2012; 120:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/13\">",
"      Haas DM, Caldwell DM, Kirkpatrick P, et al. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345:e6226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/14\">",
"      American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012; 120:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/15\">",
"      Portman DJ, Bachmann GA, Simon JA, and the Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/16\">",
"      Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/17\">",
"      Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/18\">",
"      Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol 2013; 121:172.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.drugs.com/pro/skyla-iud.html (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/21\">",
"      Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/22\">",
"      Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207:266.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/23\">",
"      The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013; 99:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/24\">",
"      Wright JD, Ananth CV, Lewin SN, et al. Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA 2013; 309:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/25\">",
"      Valle RF, Ekpo GE. Hysteroscopic metroplasty for the septate uterus: review and meta-analysis. J Minim Invasive Gynecol 2013; 20:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/26\">",
"      Verhaegen J, Gallos ID, van Mello NM, et al. Accuracy of single progesterone test to predict early pregnancy outcome in women with pain or bleeding: meta-analysis of cohort studies. BMJ 2012; 345:e6077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/27\">",
"      Kadkhodayan S, Shahriari S, Treglia G, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol 2013; 128:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/28\">",
"      Stewart LM, Holman CD, Aboagye-Sarfo P, et al. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 2013; 128:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/29\">",
"      Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/30\">",
"      Zhao D, Zhang F, Zhang W, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2013; 23:25.",
"     </a>",
"    </li>",
"    <li>",
"     NCI Press Release: Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer. file://cancer.gov/newscenter/newsfromnci/2013/GOG240 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/32\">",
"      Mavromatis ID, Antonopoulos CN, Matsoukis IL, et al. Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand 2012; 91:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/33\">",
"      Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/34\">",
"      Jonsson Funk M, Siddiqui NY, Pate V, et al. Sling revision/removal for mesh erosion and urinary retention: long-term risk and predictors. Am J Obstet Gynecol 2013; 208:73.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30264/abstract/35\">",
"      Boyle R, Hay-Smith EJ, Cody JD, M&oslash;rkved S. Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev 2012; 10:CD007471.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8350 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30264=[""].join("\n");
var outline_f29_35_30264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OBSTETRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Adverse pregnancy and birth outcomes in women with bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotic prophylaxis in obese women undergoing cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cognitive-behavioral therapy for perinatal depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management of asymptomatic neonates exposed to HSV during delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Three-dose intermittent preventive treatment of malaria during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Selective serotonin reuptake inhibitors during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tdap during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vertical transmission of hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Safety and efficacy of influenza vaccination in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      New guidelines for umbilical cord clamping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      New definitions for failed induction and labor arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy of tocolysis for preterm labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      New guideline for DNA-based aneuploidy screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OFFICE GYNECOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ospemifene for treatment of vulvovaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Long-term use of postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      New levonorgestrel-releasing IUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Levonorgestrel intrauterine device for menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Progestin therapy for endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cryopreservation of mature oocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GYNECOLOGIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Robotic versus conventional laparoscopic hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hysteroscopic metroplasty outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Serum progesterone and ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      GYNECOLOGIC ONCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PET/CT scan in the work-up of suspected recurrent endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Ovarian cancer risk, parity, and infertility treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Screening women with a familial ovarian cancer syndrome for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Hormone receptor expression and prognosis in ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Chemotherapy plus bevacizumab for recurrent, advanced, or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Intraoperative myometrial inspection for endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Duration of adjuvant tamoxifen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      UROGYNECOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Sling release after midurethral sling procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Antenatal prophylactic pelvic floor muscle exercises",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/8350\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/8350|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/63/10235\" title=\"table 1\">",
"      Designation of genital HSV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40329?source=related_link\">",
"      Bipolar disorder in women: Contraception and preconception assessment and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=related_link\">",
"      Cesarean delivery of the obese woman",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=related_link\">",
"      Levonorgestrel: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37943?source=related_link\">",
"      Management of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33368?source=related_link\">",
"      Management of recurrent or metastatic cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4629?source=related_link\">",
"      Ospemifene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=related_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29014?source=related_link\">",
"      Surgical management of congenital uterine anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_35_30265="Principles of abdominal wall incisions";
var content_f29_35_30265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of abdominal wall incisions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30265/contributors\">",
"     Jason S Mizell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30265/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30265/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/35/30265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of any open surgical procedure requires, in part, a wisely chosen incision based upon sound anatomic principles and closure with a technique that will result in a secure, well-healed wound. The surgeon is responsible for choosing the abdominal incision best suited for the planned procedure and the closure technique that will provide adequate security.",
"   </p>",
"   <p>",
"    A well-planned incision has four essential elements:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accessibility",
"     </li>",
"     <li>",
"      Extensibility",
"     </li>",
"     <li>",
"      Preservation of function",
"     </li>",
"     <li>",
"      Security",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incision must provide ready access to anticipated pathology and adequate exposure, and allow for extension if the scope of operation needs to be expanded. The incision should interfere minimally with abdominal wall function by preserving important abdominal structures. It should heal with adequate strength to reduce the risk of wound disruption and incisional hernia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17703?source=see_link\">",
"     \"Anatomy of the abdominal wall\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional considerations in selecting the type of incision include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Need for rapid entry",
"     </li>",
"     <li>",
"      Certainty of the diagnosis",
"     </li>",
"     <li>",
"      Body habitus",
"     </li>",
"     <li>",
"      Location of previous scars",
"     </li>",
"     <li>",
"      Potential for significant bleeding",
"     </li>",
"     <li>",
"      Cosmetic outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An appropriately placed incision of adequate length is enhanced by minimal tissue trauma, complete hemostasis, adept use of retractors and packs, correct posture of the patient on the operating table, and efficient illumination [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incision of the abdominal wall will be reviewed here. Closure of abdominal wall incisions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single dose of appropriately chosen prophylactic antibiotics given within one hour of abdominal incision is recommended, as this has shown to decrease the incidence of surgical site infection (SSI). Antibiotic prophylaxis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical site marking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical site marking is an important safety measure to prevent wrong site surgery. With the patient awake and before he or she is brought into the operating room, the incision site is marked with ink sufficiently indelible to remain visible following skin preparation. Surgical site marking does not affect the sterility of the surgical field [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=see_link\">",
"     \"Operating room safety\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of skin preparation is to remove dirt and contaminants by physical means and reduce bacterial concentration. Traditionally, skin preparation is accomplished with a preoperative shower, then a scrub with bactericidal soap in the operating room, followed by application of a long-acting bactericidal agent to kill bacteria pushed to the surface from skin pores during surgery.",
"   </p>",
"   <p>",
"    However, high quality data do not support a benefit from preoperative washing with or without antiseptic solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/4\">",
"     4",
"    </a>",
"    ]. Also, there appears to be no added benefit from a bactericidal scrub in the operating room performed in addition to preoperative povidone-iodine preparation of the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/5\">",
"     5",
"    </a>",
"    ]. Furthermore, use of only preoperative preparation saves time and has the potential to decrease costs. These points are illustrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of randomized trials reported a significant reduction in SSI with preoperative bathing with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      soap versus no bathing in one large trial, but not in another trial [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/4\">",
"       4",
"      </a>",
"      ]. No reduction in SSI was found for preoperative bathing with chlorhexidine soap compared with bar soap or placebo.",
"     </li>",
"     <li>",
"      A randomized trial assigned patients to a preoperative scrub with povidone-iodine soap, followed by painting with aqueous povidone-iodine versus painting with povidone-iodine solution only [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/5\">",
"       5",
"      </a>",
"      ]. There was no significant difference in the incidence of wound infection between the groups (10 percent in both groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Antiseptic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bactericidal agents should be applied in expanding concentric circles directed away from the operative site, from xiphoid to symphysis, and well beyond the iliac spines laterally. The umbilicus needs specific attention to remove debris. Some surgeons omit the preoperative application of soap, preferring only to apply the long-acting bactericidal solution.",
"   </p>",
"   <p>",
"    Novel techniques using impregnated wipes, sponges or sprays for applying the long-acting bactericidal solution seem to be equally efficacious to the traditional swabbing method [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/6\">",
"     6",
"    </a>",
"    ]. Numerous antiseptics are available, each with their own characteristics. The rate of wound infection is similar irrespective of the antiseptic solution chosen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcohol is the standard against which others are judged; however, it causes desiccation of the skin and is combustible so its use is not practical [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skin prep with insoluble iodine has been shown to reduce the incidence of SSIs. However, skin irritation is much more likely [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Povidone-iodine is a combination iodine and high molecular weight, water-soluble polymer. The slow release of iodine creates bactericidal activity against most organisms. Iodophors, however, lose some antimicrobial activity with drying and by exposure to serum proteins and blood.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       Chlorhexidine",
"      </a>",
"      is more effective against gram-positive than gram-negative organisms and has poor activity against tubercle bacteria and viruses. Its advantage is that it remains effective for over five hours [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/6,10\">",
"       6,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=see_link\">",
"       Hexachlorophene",
"      </a>",
"      is not commonly used because of a narrow spectrum of antibacterial activity and some concern because it is absorbed through the skin. It may be appropriate when patients are allergic to alternatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hair removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair only needs to be removed if it will interfere with wound closure. If hair needs to be removed, patients should be clipped rather than shaved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drapes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drapes provide a barrier during surgery that primarily serves to protect operating room personnel from exposure to body fluids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drapes can be nonocclusive or occlusive. Although iodine-impregnated drapes may reduce the number of resident skin flora, a systematic review of randomized trials that evaluated the use of adhesive drapes in cesarean section, abdominal, orthopedic, and cardiac surgery, found that adhesive drapes do not reduce the risk of surgical site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/11\">",
"     11",
"    </a>",
"    ]. A significantly higher proportion of patients in the adhesive drape group developed a surgical site infection compared with no adhesive drape (RR 1.23, 95% CI 1.02-1.48).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lighting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shadow-free lighting that is brighter than the ambient light of the operating theater should illuminate the entire length of incision. Overhead surgical lamps are usually adequate. Supplemental illumination may be provided by headlight, flexible surgical light, light mat, or combination devices that provide irrigation, suction, and illumination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Skin incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sharp scalpel is used to make a single, clean incision through the skin and into the subcutaneous tissues. In the interest of preventing wound infection, incisions are occasionally performed with two scalpels, one for the skin and one for the subcutaneous tissue. This practice is unnecessary, since no difference in wound infection rates have been found whether one or two scalpels are used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During sharp incision of the subcutaneous tissues, care should be taken to make as few blade strokes as possible. Multiple strokes result in greater tissue damage and greater susceptibility to infection. Furthermore, excessive dissection of the subcutaneous tissues should be avoided to minimize dead space. For patients who have had prior surgery at the same planned incision site, it is preferable to make the incision through the previous scar. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Reentry incisions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Controversy persists regarding the choice of scalpel or electrosurgery for incision of the subcutaneous tissues. Although animal studies have shown increased rates of wound infection and decreased wound tensile strength with the use of electrosurgery, human studies have yielded variable results. One potential explanation for these seemingly dichotomous findings is the difference between modulated (pure coagulation setting) and non-modulated (pure cutting setting) current. The non-modulated current results in vaporization of tissue and very little tissue damage, because thermal spread beyond the incision is limited. Modulated current coagulates or denatures tissue due to heat, and the thermal damage spreads beyond the point of contact. The increased volume of necrotic tissue may lead to wound infection and wound disruption. Most contemporary electrocautery generators have &ldquo;blended&rdquo; modes that provide cutting ability combined with coagulation for hemostasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of electrosurgery\", section on 'Cutting and coagulation currents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review and metaanalysis identified eleven trials comparing the outcomes of abdominal incision using cold scalpel or diathermy involving 3122 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/13\">",
"     13",
"    </a>",
"    ]. A pooled analysis found no significant differences in the rate of postoperative wound infection. The blood loss and time required to make the incision were significantly greater in the scalpel group but the differences were small (15 mL blood, 67 seconds) and probably not clinically relevant. Postoperative pain scores (visual analog scale) were significantly lower for the diathermy group in the early postoperative period (&lt;24 hours). In light of these findings, we feel that neither scalpel nor electrosurgery holds a significant benefit over the other and that electrosurgery for skin incisions is acceptable and may lower postoperative analgesic requirements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Control of superficial bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small superficial vessels that are transected will constrict, thus preventing immediate bleeding. Cauterization of these vessels leads to unnecessary tissue destruction. Large or persistently bleeding vessels in the subcutaneous tissues can be occluded with well-directed cautery or ligation with fine suture. Pinpoint cautery using the spark, rather than direct contact, will prevent excessive devitalization of tissue. Fine suture can be used to reduce inflammation. Isolation of larger vessels is best accomplished by dissection with a hemostat and suture ligation, which minimize tissue necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Exposing the abdomen and pelvis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesiolysis should be performed to allow full exploration of the abdomen and allow placement of a self-retaining retractor. Adhesions can be taken down sharply by elevating the fascia with hemostats or Kocher clamps and identifying avascular cleavage planes.",
"   </p>",
"   <p>",
"    Several wound",
"    <span class=\"nowrap\">",
"     protector/retractors",
"    </span>",
"    (eg Alexis&reg; Wound Protector) are commercially available to help retract the subcutaneous tissue out of the field while protecting it from contamination and local trauma. These devices may help to decrease the incidence of surgical site infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care should be taken not to compress structures between the retractors and the posterior abdominal wall. This risk is reduced by using lateral blades of appropriate length and elevating the retractor with towels. Iliac vessels, nerves on the psoas muscle and in the inguinal canal can be at especially high risk for inadvertent compression injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bowel is packed away from the operative field with two or three laparotomy pads to allow adequate exposure. If packing is excessively tight, venous return may be compromised leading to hypotension, and terminal nerve endings in the bowel may be unduly traumatized resulting in a prolonged ileus. Use of various operating table positions, such as the Trendelenburg or reverse Trendelenburg position, will also help to move the bowel in the upper or lower abdomen. However, the depth of Trendelenburg should not be too steep because pulmonary function can be compromised. Additionally, it has been shown that Trendelenburg position significantly increases the risk of lower extremity compartment syndrome in patients placed in the lithotomy position [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/15\">",
"     15",
"    </a>",
"    ].Gentle extension of the torso may enhance exposure, especially with transverse incisions. Patients must be returned to a neutral position when the fascia is closed to eliminate undue tension on the suture line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INCISION SELECTION AND PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous incisions are used by the surgeon operating in the abdomen and pelvis. The most important factor is to provide adequate exposure for the anticipated procedure while taking into account the possibility that the planned procedure may change depending upon intraoperative findings and complications. &nbsp;",
"   </p>",
"   <p>",
"    A systematic review found that a transverse or oblique incision may be less painful and have less impact on pulmonary function than a midline incision, particularly in the early postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/16\">",
"     16",
"    </a>",
"    ]. However, there was no difference seen in early or late postoperative complications between a transverse or oblique and a midline incision, and recovery times were similar. In addition, other studies have found that when longitudinal and transverse incisions are compared directly for the sample types of procedures, transverse incisions seem to be associated with a lower incidence of incisional hernias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and fewer postoperative bowel obstructions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/19\">",
"     19",
"    </a>",
"    ] but a higher incidence of wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/18\">",
"     18",
"    </a>",
"    ]. Although previous surgery is associated with an increased risk of bowel adhesions, vertical incisions have a higher incidence of adhesions compared with transverse incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, because adequate data supporting one incision over another are still lacking, choice of incision remains a preference of the surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LONGITUDINAL INCISIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Midline incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal incisions are often placed in the midline (",
"    <a class=\"graphic graphic_figure graphicRef63560 graphicRef59682 \" href=\"UTD.htm?25/63/26617\">",
"     figure 1A-B",
"    </a>",
"    ). Only terminal branches of the abdominal wall blood vessels and nerves are located at the linea alba, thereby limiting the potential for bleeding or nerve injury (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 2",
"    </a>",
"    ). Randomized trials have shown that midline incisions have similar rates of dehiscence when compared with transverse incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the main indications for midline incision is exploratory laparotomy (eg, trauma, abdominal sepsis). The midline incision provides the most rapid entry, which is especially important if the patient is hypotensive due to bleeding or septic shock. Additionally, the midline incision provides the greatest abdominal exposure which may be required in a seriously ill patient for whom the diagnosis or location of bleeding is uncertain. It also can be extended superiorly to the xiphoid (or to median sternotomy), inferiorly to the pubic tubercle, or transverse or oblique extensions can be added if lateral exposure is needed.",
"   </p>",
"   <p>",
"    The midline incision provides ready access to the abdominal viscera, liver, spleen, inferior vena cava, aorta, renal pedicles, kidneys, pelvic organs and vasculature. However, exposure of the posterolateral retroperitoneum, including the posterior renal hilum and retrohepatic vena cava, can be more difficult to achieve.",
"   </p>",
"   <p>",
"    The incision is made in the skin with a scalpel and carried through the subcutaneous fat sharply or using electrocautery. The midline fascia can be identified as the point where the fibers of each anterior rectus sheath join each other. For a full midline incision, and for those patients with a prior midline incision, we prefer to incise the linea alba superior to the umbilicus.",
"   </p>",
"   <p>",
"    The entire length of fascia may be divided, or some surgeons prefer to open a limited amount of fascia and complete the fascial incision after the peritoneal cavity has been entered. The preperitoneal fat is bluntly dissected from the peritoneum by sweeping the index finger or using a blunt Kelly clamp. Once identified, the peritoneum is brought up into the fascial incision with forceps or a hemostat. The author prefers to pick up and drop the peritoneum several times with forceps to allow the bowel and omentum to fall away. The elevated peritoneum is opened sharply in a longitudinal manner by incising the peritoneum adjacent to the forceps or alternatively by dividing the elevated peritoneum between two hemostats. Electrocautery should not be used to divide the peritoneum due to the risk for thermal injury to underlying bowel. Once a small opening is created, air enters the peritoneal cavity and breaks the surface tension, which allows the bowel to fall further away. The index finger is used to explore for adhesions prior to extending the incision. When identified, adhesions should not be bluntly dissected using the finger; rather, purposeful adhesiolysis with a scalpel or electrocautery will prevent tearing the serosa of any involved bowel.",
"   </p>",
"   <p>",
"    The incision is extended superiorly and inferiorly the length of which depends upon the indication. When extending superiorly, the ligamentum teres is encountered and can be taken between clamps, divided and ligated if exposure to liver is needed, or alternatively, the incision can be deviated slightly to the left to leave it intact. However, if retractors are placed into the left upper quadrant, division of the ligamentum teres prevents avulsion.",
"   </p>",
"   <p>",
"    When entering the abdominal cavity inferior to the umbilicus, care should be taken to incise the peritoneum slightly off the midline since the bladder is highest in the midline and the urachus may communicate with it (",
"    <a class=\"graphic graphic_figure graphicRef79324 \" href=\"UTD.htm?15/5/15446\">",
"     figure 3",
"    </a>",
"    ). This will reduce the risk of bladder injury, eliminate the risk of urine leaking from an incised persistent urachus, and provide better exposure. Alternatively, the urachus can be divided and ligated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/23\">",
"     23",
"    </a>",
"    ]. The bladder can be identified because of its opaqueness and markedly increased vascularity. The Foley balloon can also be pulled up to identify the upper extent of the bladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Paramedian incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paramedian incision is made 2 to 5 cm to the left or right of the midline (",
"    <a class=\"graphic graphic_figure graphicRef78609 \" href=\"UTD.htm?38/53/39768\">",
"     figure 4",
"    </a>",
"    ). The anterior rectus sheath is incised vertically, and the rectus muscle is dissected from the medial fascial edge. The muscle is retracted laterally, exposing the posterior sheath, which is incised vertically along with the peritoneum. Lateral paramedian incisions are placed at the junction of the outer one-third and inner two-thirds of the rectus muscle. In this location, the anterior rectus sheath often consists of two layers. In order to expose the posterior rectus sheath, the rectus muscle is separated vertically.",
"   </p>",
"   <p>",
"    Paramedian incisions can be extended into the upper abdomen without the difficulties of curving around the umbilicus. The paramedian incision may decrease the risk of dehiscence or hernia as compared to midline incisions, although conflicting data have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These incisions take longer to perform, restrict access to the contralateral pelvis, and risk injury to the epigastric vessels. In addition, nerve injury may result in rectus paralysis. The closure of paramedian incisions is similar to the closure of midline longitudinal incisions, although mass closure may be more difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pararectus incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pararectus incision (also known as Battle's incision) is placed at the lateral border of the rectus muscle, which is retracted medially. This infrequently utilized incision was used primarily for appendectomy or drainage of pelvic abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/26\">",
"     26",
"    </a>",
"    ]. It causes denervation of the rectus, resulting in paralysis and ultimately muscle atrophy. The length of this incision must be restricted to no more than two dermatomes to prevent weakness of the abdominal wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294621\">",
"    <span class=\"h1\">",
"     OBLIQUE INCISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several oblique incisions are used for specific anatomic exposures (",
"    <a class=\"graphic graphic_figure graphicRef58517 \" href=\"UTD.htm?0/46/740\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294799\">",
"    <span class=\"h2\">",
"     McBurney's incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;McBurney's incision is an oblique muscle-splitting incision located one third of the way from the iliac spine to the umbilicus (",
"    <a class=\"graphic graphic_figure graphicRef76933 \" href=\"UTD.htm?37/61/38866\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/27\">",
"     27",
"    </a>",
"    ]. An oblique incision is made in the skin along Langer's lines. The fibers of the external oblique, internal oblique and transversus abdominis are sequentially separated along their fibers (",
"    <a class=\"graphic graphic_figure graphicRef63567 \" href=\"UTD.htm?11/31/11764\">",
"     figure 7",
"    </a>",
"    ). The peritoneum and transversalis fascia are exposed and incised parallel to the skin incision.",
"   </p>",
"   <p>",
"    Retractors may be used to stretch the incision for better exposure. If exposure is still not adequate, the incision may be first expanded laterally and upward, and then medially if necessary. Lateral extension may be made following the fibers of the external oblique muscle. Further medial access can be obtained by incising the anterior rectus sheath and rectus muscle. The epigastric vessels should be identified and possibly ligated to avoid bleeding.",
"   </p>",
"   <p>",
"    Although the muscles will reapproximate by contraction, closure of the muscle fascia is performed. The transverse abdominis and internal oblique are reapproximated with loosely tied interrupted absorbable sutures (",
"    <a class=\"graphic graphic_figure graphicRef70883 \" href=\"UTD.htm?43/2/44065\">",
"     figure 8",
"    </a>",
"    ). The aponeurosis of the external oblique may be closed with interrupted or continuous absorbable suture.",
"   </p>",
"   <p>",
"    McBurney's incision provides excellent access to the ipsilateral lower quadrant, making it ideal for appendectomy. The incision may be placed lower for extraperitoneal drainage of a pelvic abscess. It is easily expanded and cosmesis is excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294806\">",
"    <span class=\"h3\">",
"     Rockey-Davis or Elliot modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incision may also be placed transversely (as opposed to obliquely, like the McBurney&rsquo;s incision) between the junction of the lower and middle third of a line from the superior anterior iliac spine to the umbilicus and the lateral border of the rectus abdominis muscle (also known as a Rockey-Davis incision or Elliot incision). The aponeurotic layers are opened in a fashion similar to McBurney's incision. This incision is thought to be cosmetically superior to the McBurney&rsquo;s incision. Additionally, the incision may be made on the left or lower to gain better access to a pelvic abscess. Exposure to the ipsilateral lower quadrant is excellent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294660\">",
"    <span class=\"h2\">",
"     Subcostal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subcostal and bilateral subcostal (chevron) incisions are used to access the upper abdomen and flank and can be used for open cholecystectomy, bile duct surgery, liver resection, liver transplant, duodenal surgery, adrenalectomy, and open nephrectomy, among other surgeries. The subcostal or chevron incision can also be extended to a sternotomy incision (also known as the Mercedes-Benz incision) when cardiopulmonary bypass or liver mobilization is needed.",
"   </p>",
"   <p>",
"    The skin incision is placed about 3 cm below and parallel to the costal margin. The fascia of the rectus muscle medially and the external oblique muscles are initially divided. Next, the rectus muscle and the external oblique, internal oblique, and transversalis muscles are divided. When dividing the rectus muscle, the superior epigastric vessels should be identified and divided between clamps and ligated.",
"   </p>",
"   <p>",
"    Disadvantages of a subcostal approach include poor cosmesis and increased postoperative pain, particularly with bilateral subcostal incisions. For this reason, some surgeons prefer epidural for postoperative analgesia, which can minimize the discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294667\">",
"    <span class=\"h2\">",
"     Thoracoabdominal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thoracoabdominal approach is a transthoracic intra- or extraperitoneal approach that provides exposure to the kidney, adrenal, lung and inferior vena cava (right) and aorta (left). It is the preferred approach for open thoracoabdominal aortic surgery and for intravenous tumor thrombus extending into the IVC, since it allows mobilization of the liver and complete IVC exposure up to the heart. The disadvantages of the thoracoabdominal approach include the potential for thoracic complications (hernia, phrenic nerve injury, pneumothorax), postoperative chest tube requirement, and a prolonged operative time.",
"   </p>",
"   <p>",
"    For this approach, the patient is placed in semi-lateral position, with both hips on the operating table. The thorax ipsilateral to the operated side is rotated 45 degrees over a rolled towel and the ipsilateral arm is placed over an arm support. The incision is performed over the 9",
"    <sup>",
"     th",
"    </sup>",
"    or 10",
"    <sup>",
"     th",
"    </sup>",
"    rib and extended to the midline for an intraabdominal approach (inverted hockey stick incision), to the contralateral subcostal region, or to between the umbilicus and pubis for a retroperitoneal approach (",
"    <a class=\"graphic graphic_figure graphicRef58517 \" href=\"UTD.htm?0/46/740\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After the incision is cut down to the selected rib, the rib and the cartilage are exposed, and the intercostal muscles are incised with cautery followed by division of the pleura. Care is taken to avoid injury the lung. The external oblique, internal oblique, transverse, and rectus muscles are divided with cautery. The rectus muscle can usually be spared with a retroperitoneal approach. If a transperitoneal approach is selected, the peritoneum is opened between clamps, whereas care is taken to preserve the peritoneum for a retroperitoneal approach by reflecting it medially off Gerota&rsquo;s fascia. If the peritoneum is inadvertently divided, it can be repaired with absorbable suture to prevent herniation of the intestines into the operative field. The cartilage above the selected rib is cut with heavy Mayo scissors and the diaphragm is divided medially, avoiding the phrenic nerves (",
"    <a class=\"graphic graphic_figure graphicRef77888 \" href=\"UTD.htm?16/29/16857\">",
"     figure 9",
"    </a>",
"    ). Following completion of the procedure, the diaphragm is closed with a 0-prolene running suture. The ribs are reapproximated with absorbable suture after a chest tube is positioned in the thorax at a location several intercostal spaces above the level of the incision in the midaxillary line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TRANSVERSE INCISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse incisions were initially developed to minimize likelihood of fascial dehiscence and incisional hernias. However, a study evaluating only gynecologic surgery patients found no difference in fascial dehiscence between transverse (Pfannenstiel) and vertical incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/21\">",
"     21",
"    </a>",
"    ]. Since these incisions follow Langer's lines, less tension exists across transverse incisions, and the cosmetic result is enhanced (",
"    <a class=\"graphic graphic_figure graphicRef76685 \" href=\"UTD.htm?16/48/17155\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294974\">",
"    <span class=\"h2\">",
"     Abdominal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse incisions above or below the umbilicus are occasionally used to access the abdominal organs. A transverse extension of a midline incision may also be used to gain additional exposure. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Midline incision'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294946\">",
"    <span class=\"h2\">",
"     Flank",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flank incision is a retroperitoneal approach that provides good exposure to the retroperitoneal structures without the need to open the peritoneum and is an excellent approach for radical, simple and partial nephrectomy. It is useful for avoiding contamination of the peritoneum when active infection of the kidney is present (eg, emphysematous pyelonephritis).",
"   </p>",
"   <p>",
"    The advantages of the flank approach include the relatively small size of the incision, direct access to the kidney, no need to mobilize the colon, and a retroperitoneal-only dissection, which minimizes postoperative ileus.",
"   </p>",
"   <p>",
"    Disadvantages include poor access to the inferior vena cava and aorta and limited exposure of the upper pole of the kidney, particularly on the left side. Given the proximity of the pleura, pneumothorax or other thoracic complications can occur.",
"   </p>",
"   <p>",
"    The patient is placed in full lateral position with the ipsilateral arm placed overhead on an arm support. An axillary roll is placed under the patient&rsquo;s thorax to decrease pressure on the dependent shoulder and axilla, and the contralateral leg is bent at the hip and knee while the ipsilateral leg is kept straight. The table is then flexed to stretch the flank. A kidney rest can be used to temporarily elevate and further flex the patient; however, it should not be used for more than four hours, particularly in obese patients, due to the potential for compression. Rhabdomyolysis has been reported after prolonged use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The flank incision is performed at the superior margin of the 10th, 11th or 12th rib and extended toward the midline. The latissimus dorsi, intercostal, external oblique, internal oblique and transversalis muscles are divided using electrocautery. The peritoneum is then reflected medially off Gerota&rsquo;s fascia exposing the retroperitoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294920\">",
"    <span class=\"h3\">",
"     Lumbotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbotomy is used mainly for nephrectomy involving small nonfunctional kidneys and for pediatric pyeloplasty. A transverse incision is placed between the 12th rib and the iliac crest perpendicular to the sacrospinalis muscle. After the incision of the lumbodorsal fascia, the sacrospinalis and quadratus muscles are retracted medially, the transversalis fascia is opened and Gerota&rsquo;s fascia is entered. The main advantages of the lumbotomy include avoidance of muscle, decreased postoperative pain, and direct access to the renal pelvis and ureter. Disadvantages include poor access to the renal vessels and difficult dissection in the face of renal masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3294939\">",
"    <span class=\"h2\">",
"     Incisions for pelvic operations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest disadvantages of transverse incisions are the limited exposure provided to the upper abdomen, limited extensibility, increased surgical time and relatively larger blood loss. Low transverse incisions can also be problematic if the pannus is large.",
"   </p>",
"   <p>",
"    All of the incisions described below begin with a transverse skin incision centered above the symphysis pubis. The different incisions are distinguished by their distance above the symphysis. They may be straight or have a gentle curve with cephalic concavity. Several vertical marks can be placed across the incision line to aide in symmetrical reapproximation. This is especially helpful if the incision is curved. Placing the incisions in the public hair line or in a natural skin crease may enhance the cosmetic result. However, the incision should not be placed in a deep skin fold of a large panniculus where maceration of the skin can increase the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H21#H21\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Morbid obesity'",
"    </a>",
"    .) The subcutaneous tissue is initially incised transversely with all approaches.",
"   </p>",
"   <p>",
"    Transverse incisions for pelvic surgery are of four types (",
"    <a class=\"graphic graphic_figure graphicRef68150 \" href=\"UTD.htm?41/15/42228\">",
"     figure 11",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pfannenstiel's incision, a muscle-separating operation (most common)",
"     </li>",
"     <li>",
"      Cherney's incision, a tendon-detaching operation",
"     </li>",
"     <li>",
"      Maylard's incision, a true muscle-cutting incision",
"     </li>",
"     <li>",
"      K&uuml;stner's incision, a median incision using a transverse skin incision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Pfannenstiel incision and the Maylard incision have been compared directly with cesarean delivery and were judged to be comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/30\">",
"     30",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Pfannenstiel's incision'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pfannenstiel's incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pfannenstiel's incision, the most popular transverse incision for pelvic surgery, is placed 2 to 5 cm above the pubic symphysis and usually is 10 to 15 cm in length (",
"    <a class=\"graphic graphic_figure graphicRef79430 \" href=\"UTD.htm?5/49/5913\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/23\">",
"     23",
"    </a>",
"    ]. After the skin is entered, the incision is carried through the subcutaneous tissue to the anterior rectus sheath, which is incised transversely. The upper and lower fascial edges are grasped with a heavy toothed clamp, such as a Kocher, elevated, and dissected bluntly and sharply off the underlying rectus muscle from the umbilicus to the symphysis. The rectus muscle is separated along the midline raphe, exposing the transversalis fascia and the posterior rectus sheath. These layers and the peritoneum are incised vertically.",
"   </p>",
"   <p>",
"    Closure of Pfannenstiel's incision may include loose reapproximation of the rectus muscles at the midline, if diastasis is present. Otherwise, the rectus muscles reapproximate themselves. The anterior rectus sheath may be closed with absorbable or nonabsorbable suture in an interrupted fashion.",
"   </p>",
"   <p>",
"    Pfannenstiel's incision provides excellent strength and cosmesis, and exposure is adequate for procedures limited to the pelvis, however, there is minimal opportunity to extend the incision if wider exposure is desired. This incision is used only when pathology is confined to the pelvis. However, the Pfannenstiel incision may be modified in a Cherney manner for improved exposure (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Cherney's incision'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Since several tissue planes must be opened, speed of entry is restricted, and the risk of seroma, hematoma, and wound infection may be increased. Because of these considerations, this incision is relatively contraindicated in the presence of active abdominal infection or if speed is of the essence.",
"   </p>",
"   <p>",
"    Dissection of the lower rectus sheath has been standard practice in performing a Pfannenstiel incision for Caesarean section. The need to separate the rectus sheath from the rectus muscles has been evaluated. A randomized trial found a significant reduction in post-operative pain and reduced blood loss in patients who did not undergo dissection of the rectus sheath compared with those who did [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of inguinal hernia with the Pfannenstiel incision, at least in men, may be greater when the incision is close to the external inguinal ring [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/24\">",
"     24",
"    </a>",
"    ]. If the incision is extended beyond the rectus muscle, the iliohypogastric and ilioinguinal nerves may be encountered. Neuromas can occur if these nerves are traumatized and some patients will experience chronic pain severe enough to limit daily activities.",
"   </p>",
"   <p>",
"    Significant predictors of chronic pain following Caesarean section include numbness after a primary incision, repeat Pfannenstiel incision and emergency procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/32\">",
"     32",
"    </a>",
"    ]. In this study, over half the patients with moderate to severe pain had evidence of nerve entrapment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cherney's incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cherney's incision is similar to the Pfannenstiel incision, except it involves incising the rectus tendons and is placed slightly lower on the abdomen (",
"    <a class=\"graphic graphic_figure graphicRef73105 \" href=\"UTD.htm?6/54/7016\">",
"     figure 13",
"    </a>",
"    ). Like Pfannenstiel's incision, the anterior rectus sheath is incised in transverse fashion, and may be dissected from the muscle superiorly and inferiorly. The tendons of the rectus and pyramidalis muscles are incised at their insertion to the symphysis following blunt separation from the underlying bladder and adventitial tissue. A half centimeter segment of tendon is left on the symphysis for reattachment. The muscles and tendons are retracted caudad, and the peritoneum is incised longitudinally.",
"   </p>",
"   <p>",
"    Closure of Cherney's incision requires reattachment of the muscle tendons to their insertions. This is usually accomplished using permanent horizontal mattress sutures. Alternatively, the tendons may be attached to the lower rectus sheath.",
"   </p>",
"   <p>",
"    Cherney's incision provides excellent exposure to the retropubic space of Retzius, making it a good choice for retropubic urethropexy. A Pfannenstiel incision may be converted to a Cherney incision to enhance exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Maylard's incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maylard's incision (also known as the Mackenrodt incision) is a transverse incision through all layers of the abdominal wall usually at the level of the anterior iliac spine (",
"    <a class=\"graphic graphic_figure graphicRef53422 \" href=\"UTD.htm?31/13/31960\">",
"     figure 14",
"    </a>",
"    ). Following wide transverse incision in the aponeurosis, the rectus muscles are incised transversely with a scalpel, electrosurgery, or surgical stapler.",
"   </p>",
"   <p>",
"    Prior to transection of the muscles, the deep inferior epigastric vessels are identified on their lateral undersurface. The vessels are isolated, clamped, transected, and ligated. During transection of the rectus muscles, dissection from the anterior rectus sheath should be avoided in order to limit retraction of the muscles. In addition, the cut edge of the muscle may be secured to the anterior sheath with 0-caliber absorbable mattress sutures to further prevent retraction.",
"   </p>",
"   <p>",
"    The Maylard incision can provide adequate abdominal and pelvic exposure. One study found that the extent of anterior abdominal wall adhesions at secondary cytoreductive surgery were minimal with this incision [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/33\">",
"     33",
"    </a>",
"    ]. As with other transverse incisions, the Maylard incision can limit access to the upper abdomen depending on the patient's body habitus, and delayed bleeding from the cut edge of the rectus muscle or deep epigastric vessels can occur.",
"   </p>",
"   <p>",
"    A serious and often unanticipated complication of the Maylard incision can occur in patients with significant aortoiliac occlusion (eg, aortic atherosclerosis or coarctation). These patients depend upon collateral flow from the epigastric vessels for perfusion of the lower extremities (",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"UTD.htm?11/30/11753\">",
"     figure 2",
"    </a>",
"    ). The ligation of these epigastrics during a Maylard incision may cause worsening symptoms of lower extremity ischemia such as claudication and even acute leg ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     K&uuml;stner's incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;K&uuml;stner's incision is begun with a transverse skin incision approximately 5 cm above the symphysis and just below the anterior iliac spine (",
"    <a class=\"graphic graphic_figure graphicRef81017 \" href=\"UTD.htm?41/36/42565\">",
"     figure 15",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/34\">",
"     34",
"    </a>",
"    ]. Subcutaneous adipose is then separated from the rectus sheath in a vertical plane to reveal the linea alba. Numerous small branches of the superficial epigastric plexus of vessels may be encountered and must be ligated to prevent excess oozing. Because of the need for extensive hemostasis, this incision tends to be very time-consuming. Care must be taken to dissect only enough to expose the linea alba and not to separate the subcutaneous tissue too far laterally. A vertical midline incision is then made in the linea alba. The procedure for the midline incision is subsequently followed (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Midline incision'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    K&uuml;stner's incision combines the disadvantages of both midline and transverse incisions and therefore has limited utility. Collection of blood and serum increases the risk of infection and may necessitate drainage. The incision affords less exposure than the Pfannenstiel and almost no extensibility. It was developed to reduce the risk of evisceration; however, the incidence of herniation is similar to midline incisions. The author normally uses this incision only to avoid intersecting skin incisions when reoperation is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Turner-Warwick's incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turner-Warwick's incision is centered 2 to 3 cm above the symphysis and placed within the lateral borders of the rectus muscles (",
"    <a class=\"graphic graphic_figure graphicRef60715 \" href=\"UTD.htm?21/8/21640\">",
"     figure 16",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/35\">",
"     35",
"    </a>",
"    ]. The lower pole of the rectus muscles from below the symphysis are separated from the overlying sheath. The aponeurosis incision is usually 2 cm below the symphysis and 4 cm across. The rectus sheath incision is angled upward to the lateral border of the rectus, but remains medial to the internal oblique and transversus abdominis muscle bellies. A Kocher clamp can be placed on the aponeurosis for traction as it is separated from the muscle by blunt and sharp dissection. The pyramidalis muscles usually remain attached to the aponeurosis. The rectus muscles are separated from the transversalis fascia and the peritoneum is incised in the midline.",
"   </p>",
"   <p>",
"    The Turner-Warwick incision provides excellent exposure to the retropubic space, but upper pelvis and abdominal exposure is severely limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     REENTRY INCISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have had prior surgery at the same planned incision site, it is preferable to make the incision through the previous scar, since the placement of parallel incisions may result in an intervening bridge of ischemic tissue, even if the incisions are performed many years apart [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/36\">",
"     36",
"    </a>",
"    ]. If the prior scar is cosmetically unacceptable, it may be excised at the beginning or end of the procedure. This is easily accomplished by elevating the old scar with Allis clamps and making an elliptical incision around the old scar.",
"   </p>",
"   <p>",
"    Ischemia and necrosis may also occur at points of intersection of the incisions.",
"   </p>",
"   <p>",
"    As noted above, it is usually preferable to extend the skin and fascial incision a few centimeters above the previous incision so the peritoneum can be opened where it is relatively free of adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS FOR OBESE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incisions should not be placed within the overlapping fold of a panniculus due to the anaerobic bacterial load [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/37\">",
"     37",
"    </a>",
"    ]. Several strategies have been described to avoid incision placement in this area. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link&amp;anchor=H21#H21\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\", section on 'Morbid obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The panniculus may be grasped with towel clamps and pulled down. The skin incision is then placed in a paramedian or midline location extending above the umbilicus. While the topography of the abdomen is distorted, the fascial anatomy is not. A protocol utilizing this technique has been shown to lower the rate of wound infection from 42 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach is removal of the panniculus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/39\">",
"     39",
"    </a>",
"    ]. In a review of panniculectomy, the rate of wound infection was 2.6 percent. A further advantage of this procedure is that the depth of the surgical field is significantly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30265/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial incision can be made using a scalpel or electrosurgery wand. During sharp incision of the subcutaneous tissues, care should be taken to make as few blade strokes as possible. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Skin incision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important factor in selecting an incision is ensuring it will provide adequate exposure for the anticipated procedure while taking into account the possibility that the planned procedure may change depending upon intraoperative findings and complications. Other factors to consider include speed, blood loss, cosmetic appearance, and the presence of co-morbid conditions. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Incision selection and placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The midline incision is the most versatile longitudinal incision. It provides the quickest entry and the best exposure and extensibility. It is a good choice for patients who are anticoagulated, who have enlarged epigastric vessels that may be injured, who have intraabdominal infection, or who may need an extended incision. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Midline incision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major advantage of transverse incisions is cosmetic. Disadvantages include the limited exposure provided to the upper abdomen, limited extensibility, increased surgical time and relatively larger blood loss. Low transverse incisions can also be problematic if the pannus is large. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Transverse incisions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reentry incisions should be performed through the previous incision whenever possible. Adhesions are expected at the site of the prior incision. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Reentry incisions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incisions should not be placed in the overlapping fold of a large pannus. Panniculectomy may facilitate surgery in the very obese patient and reduce the risk of wound infection. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Special considerations for obese patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/1\">",
"      Meeks GR, Trenhaile TR. Management of abdominal incisions. J Pel Surg 2002; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/2\">",
"      Rooney J, Khoo OK, Higgs AR, et al. Surgical site marking does not affect sterility. ANZ J Surg 2008; 78:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/3\">",
"      Zhao X, Chen J, Fang XQ, Fan SW. Surgical site marking will not affect sterility of the surgical field. Med Hypotheses 2009; 73:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/4\">",
"      Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2007; :CD004985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/5\">",
"      Ellenhorn JD, Smith DD, Schwarz RE, et al. Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sites. J Am Coll Surg 2005; 201:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/6\">",
"      Edmiston CE Jr, Seabrook GR, Johnson CP, et al. Comparative of a new and innovative 2% chlorhexidine gluconate-impregnated cloth with 4% chlorhexidine gluconate as topical antiseptic for preparation of the skin prior to surgery. Am J Infect Control 2007; 35:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/7\">",
"      Berry AR, Watt B, Goldacre MJ, et al. A comparison of the use of povidone-iodine and chlorhexidine in the prophylaxis of postoperative wound infection. J Hosp Infect 1982; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/8\">",
"      Laufman H. Current use of skin and wound cleansers and antiseptics. Am J Surg 1989; 157:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/9\">",
"      Segal CG, Anderson JJ. Preoperative skin preparation of cardiac patients. AORN J 2002; 76:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/10\">",
"      Peterson AF, Rosenberg A, Alatary SD. Comparative evaluation of surgical scrub preparations. Surg Gynecol Obstet 1978; 146:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/11\">",
"      Webster J, Alghamdi AA. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev 2007; :CD006353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/12\">",
"      Hasselgren PO, Hagberg E, Malmer H, et al. One instead of two knives for surgical incision. Does it increase the risk of postoperative wound infection? Arch Surg 1984; 119:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/13\">",
"      Ahmad NZ, Ahmed A. Meta-analysis of the effectiveness of surgical scalpel or diathermy in making abdominal skin incisions. Ann Surg 2011; 253:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/14\">",
"      Horiuchi T, Tanishima H, Tamagawa K, et al. Randomized, controlled investigation of the anti-infective properties of the Alexis retractor/protector of incision sites. J Trauma 2007; 62:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/15\">",
"      Chase J, Harford F, Pinzur MS, Zussman M. Intraoperative lower extremity compartment pressures in lithotomy-positioned patients. Dis Colon Rectum 2000; 43:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/16\">",
"      Brown SR, Goodfellow PB. Transverse verses midline incisions for abdominal surgery. Cochrane Database Syst Rev 2005; :CD005199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/17\">",
"      Fassiadis N, Roidl M, Hennig M, et al. Randomized clinical trial of vertical or transverse laparotomy for abdominal aortic aneurysm repair. Br J Surg 2005; 92:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/18\">",
"      Seiler CM, Deckert A, Diener MK, et al. Midline versus transverse incision in major abdominal surgery: a randomized, double-blind equivalence trial (POVATI: ISRCTN60734227). Ann Surg 2009; 249:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/19\">",
"      Inaba T, Okinaga K, Fukushima R, et al. Prospective randomized study of two laparotomy incisions for gastrectomy: midline incision versus transverse incision. Gastric Cancer 2004; 7:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/20\">",
"      Levrant SG, Bieber E, Barnes R. Risk of Anterior Abdominal Wall Adhesions Increases with Number and Type of Previous Laparotomy. J Am Assoc Gynecol Laparosc 1994; 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/21\">",
"      Hendrix SL, Schimp V, Martin J, et al. The legendary superior strength of the Pfannenstiel incision: a myth? Am J Obstet Gynecol 2000; 182:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/22\">",
"      Ellis H, Coleridge-Smith PD, Joyce AD. Abdominal incisions--vertical or transverse? Postgrad Med J 1984; 60:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/23\">",
"      EVERETT HS, MATTINGLY RF. Urinary tract injuries resulting from pelvic surgery. Am J Obstet Gynecol 1956; 71:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/24\">",
"      Cox PJ, Ausobsky JR, Ellis H, Pollock AV. Towards no incisional hernias: lateral paramedian versus midline incisions. J R Soc Med 1986; 79:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/25\">",
"      Guillou PJ, Hall TJ, Donaldson DR, et al. Vertical abdominal incisions--a choice? Br J Surg 1980; 67:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/26\">",
"      Yamada M, Maruta K, Shiojiri Y, et al. Atrophy of the abdominal wall muscles after extraperitoneal approach to the aorta. J Vasc Surg 2003; 38:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/27\">",
"      McBurney C. IV. The Incision Made in the Abdominal Wall in Cases of Appendicitis, with a Description of a New Method of Operating. Ann Surg 1894; 20:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/28\">",
"      Delany HM, Carnevale NJ. A \"Bikini\" incision for appendectomy. Am J Surg 1976; 132:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/29\">",
"      Akhavan A, Gainsburg DM, Stock JA. Complications associated with patient positioning in urologic surgery. Urology 2010; 76:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/30\">",
"      Giacalone PL, Daures JP, Vignal J, et al. Pfannenstiel versus Maylard incision for cesarean delivery: A randomized controlled trial. Obstet Gynecol 2002; 99:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/31\">",
"      Kadir RA, Khan A, Wilcock F, Chapman L. Is inferior dissection of the rectus sheath necessary during Pfannenstiel incision for lower segment Caesarean section? A randomised controlled trial. Eur J Obstet Gynecol Reprod Biol 2006; 128:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/32\">",
"      Loos MJ, Scheltinga MR, Mulders LG, Roumen RM. The Pfannenstiel incision as a source of chronic pain. Obstet Gynecol 2008; 111:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/33\">",
"      Fanning J, Pruett A, Flora RF. Feasibility of the Maylard transverse incision for ovarian cancer cytoreductive surgery. J Minim Invasive Gynecol 2007; 14:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/34\">",
"      K&uuml;stner O. Der suprasymphysare kreuzscnitt, eine methode der coeliotomie bei wenig umfanglichen affektioen der weiblichen beckenorgane. Monatsschr Geburtsh Gyn&auml;kol 1986; 4:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/35\">",
"      Warwick RT, Worth P, Milroy E, Duckett J. The suprapubic V-incision. Br J Urol 1974; 46:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/36\">",
"      Nygaard IE, Squatrito RC. Abdominal incisions from creation to closure. Obstet Gynecol Surv 1996; 51:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/37\">",
"      Alexander CI, Liston WA. Operating on the obese woman--A review. BJOG 2006; 113:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/38\">",
"      Gallup DG. Modifications of celiotomy techniques to decrease morbidity in obese gynecologic patients. Am J Obstet Gynecol 1984; 150:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/39\">",
"      Hopkins MP, Shriner AM, Parker MG, Scott L. Panniculectomy at the time of gynecologic surgery in morbidly obese patients. Am J Obstet Gynecol 2000; 182:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30265/abstract/40\">",
"      Olejek A, Manka G. Panniculectomy in gynecologic cancer surgical procedures by using a harmonic scalpel. Acta Obstet Gynecol Scand 2005; 84:690.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30265=[""].join("\n");
var outline_f29_35_30265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical site marking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Antiseptic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hair removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drapes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lighting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Skin incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Control of superficial bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Exposing the abdomen and pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INCISION SELECTION AND PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LONGITUDINAL INCISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Midline incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Paramedian incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pararectus incision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3294621\">",
"      OBLIQUE INCISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3294799\">",
"      McBurney's incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3294806\">",
"      - Rockey-Davis or Elliot modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3294660\">",
"      Subcostal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3294667\">",
"      Thoracoabdominal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TRANSVERSE INCISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3294974\">",
"      Abdominal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3294946\">",
"      Flank",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3294920\">",
"      - Lumbotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3294939\">",
"      Incisions for pelvic operations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pfannenstiel's incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cherney's incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Maylard's incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - K&uuml;stner's incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Turner-Warwick's incision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      REENTRY INCISIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SPECIAL CONSIDERATIONS FOR OBESE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/56/16259\" title=\"figure 1A\">",
"      Vertical skin incisions of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/46/22246\" title=\"figure 1B\">",
"      Midline incision of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/30/11753\" title=\"figure 2\">",
"      Blood vessels of the anterior abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/5/15446\" title=\"figure 3\">",
"      Anomalies of the urachus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/53/39768\" title=\"figure 4\">",
"      Paramedian incision of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/46/740\" title=\"figure 5\">",
"      Oblique incisions of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/61/38866\" title=\"figure 6\">",
"      McBurney incision 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/31/11764\" title=\"figure 7\">",
"      McBurney incision 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/2/44065\" title=\"figure 8\">",
"      McBurney incision 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/29/16857\" title=\"figure 9\">",
"      Surfaces of the diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/48/17155\" title=\"figure 10\">",
"      Langers lines of the abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/15/42228\" title=\"figure 11\">",
"      Transverse incisions of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/49/5913\" title=\"figure 12\">",
"      Pfannenstiel incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/54/7016\" title=\"figure 13\">",
"      Cherney incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/13/31960\" title=\"figure 14\">",
"      Maylard incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/36/42565\" title=\"figure 15\">",
"      Kustner incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21640\" title=\"figure 16\">",
"      Turner-Warwick incision",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/18/17703?source=related_link\">",
"      Anatomy of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33369?source=related_link\">",
"      Operating room safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_35_30266="Health hazards associated with obesity in adults";
var content_f29_35_30266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Health hazards associated with obesity in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30266/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30266/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30266/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30266/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/35/30266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/35/30266/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/35/30266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity and mortality associated with being overweight or obese have been known to the medical profession for more than 2000 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/1\">",
"     1",
"    </a>",
"    ]. Overweight refers to a weight above the \"normal\" range. This is determined by calculating the body mass index (BMI, defined as the weight in kilograms divided by height in meters squared). Overweight is defined as a BMI of 25 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    obesity as a BMI of &gt;30",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    Severe obesity is defined as a BMI &gt;40",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (or &ge;35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    in the presence of comorbidities).",
"   </p>",
"   <p>",
"    The health hazards associated with obesity are reviewed here. The prevalence of and therapy for obesity, and the evaluation of the overweight patient are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of large epidemiologic studies have evaluated the relationship between obesity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/2-11\">",
"     2-11",
"    </a>",
"    ]. In general, greater BMI is associated with increased rate of death from all causes and from cardiovascular disease (CVD) (",
"    <a class=\"graphic graphic_figure graphicRef73156 \" href=\"UTD.htm?7/2/7200\">",
"     figure 1",
"    </a>",
"    ). This is particularly true for those with severe obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/6\">",
"     6",
"    </a>",
"    ]. Estimates for the annual number of excess deaths attributable to obesity in the United States are variable and range from 111,909 to 365,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Being overweight also appears to be associated with decreased survival in some [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/4,10,14\">",
"     4,10,14",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/15\">",
"     15",
"    </a>",
"    ] studies. As an example, a prospective study from the United States evaluated the relationship between BMI and risk of death over a maximum follow-up period of 10 years among over 500,000 men and women aged 50 to 71 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/4\">",
"     4",
"    </a>",
"    ]. Among the subset of individuals 50 years of age (when prevalence of chronic disease is low) who had never smoked, an increased risk of death was associated with being either overweight (20 to 50 percent increase in those between 26.5 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    or obese (two- to over threefold increase in those &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"    The risk of all-cause mortality with increasing BMI of 25",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    or higher appears to be independent of gender and ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/4,16\">",
"     4,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in the Prospective Studies Collaboration analysis of 57 prospective studies (894,000 European and North American adults followed for a mean of eight years), in a pooled analysis of 19 prospective studies (1.4 million Caucasian adults with median follow-up of 10 years) from the National Cancer Institute Cohort Consortium (NCICC), and in a pooled analysis of 19 prospective cohort studies (1.1 million Asian adults with mean follow-up of nine years) from the Asia Cohort Consortium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/10,14,17\">",
"     10,14,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Prospective Studies analysis, mortality was lowest among men and women with a BMI between 22.5 to 25",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    and there was a 30 percent increase in overall mortality for each 5",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    increase in BMI (",
"    <a class=\"graphic graphic_figure graphicRef73156 \" href=\"UTD.htm?7/2/7200\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/10\">",
"     10",
"    </a>",
"    ]. In an analysis of studies from the NCICC that was restricted to participants who never smoked and did not have diagnosed cancer or heart disease, a BMI of 20 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    was associated with the lowest all-cause mortality, and there was a similar 30 percent increase in mortality per 5 unit increase in BMI in the 25 to 49.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    range [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a meta-analysis of 97 studies (2.88 million individuals) showed that, compared with normal weight, being overweight was associated with a lower all-cause mortality (HR 0.94, 95% CI0.91-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/15\">",
"     15",
"    </a>",
"    ]. The results were similar after adjustment for smoking status, preexisting disease, and weight and height reporting method (measured or self reported). In addition, in a study to date of 5010 men with a history of myocardial infarction or stroke, elevated BMI was not strongly associated with an increase in either cardiovascular or total mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of factors that may help explain the wide variability in the overweight and obesity-related mortality estimates. As an example, BMI is affected by diet and exercise habits, which may affect health (and mortality) in ways that may be mediated by BMI or independent of it. In addition, variable choice of statistical techniques and study populations affect estimates of mortality risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate question is related to outcomes in individuals with lower BMI values. The following observations illustrate the range of findings from variably defined patient populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Prospective Studies Collaboration, subjects with BMI below 22.5",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      had higher mortality compared with subjects with a BMI of 22.5 to 25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/10\">",
"       10",
"      </a>",
"      ]. The excess mortality was predominantly due to smoking-related diseases (respiratory and cancer).",
"     </li>",
"     <li>",
"      In the analysis of studies from the NCICC, mortality risk was significantly higher among participants with BMI below 22.5",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      (HR 2.02, 95% CI 1.94-2.11, for women with a BMI of 15 to 18.4 compared with 22.5 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/14\">",
"       14",
"      </a>",
"      ]. However, the increased mortality rate among those with a BMI below 22.5",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      was lower in those who were healthy and never smoked compared with all participants (HR 1.47 versus 2.02 and 1.37 versus 1.98 for women and men, respectively, with BMI 15 to 18.4 versus 22.5 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m2).",
"      </span>",
"      In addition, the association between underweight and increased mortality among healthy subjects who never smoked was weaker after 15 years of follow-up than after five years of follow-up (HRs 1.21 and 1.73, respectively).",
"     </li>",
"     <li>",
"      In the Asian Cohort Consortium, both East Asian and Indian and Bangladeshi populations with BMI below 20.1",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      had significantly higher mortality compared with subjects with BMI of 22.6 to 25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      (HRs 1.84 and 1.59, respectively, for BMI 15.1 to 17.5",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/17\">",
"       17",
"      </a>",
"      ]. When the analysis was limited to nonsmokers, the elevated risk was attenuated but remained significant (HRs 1.72 and 1.54).",
"     </li>",
"     <li>",
"      A report from the National Health and Nutrition Examination Survey (NHANES) defined underweight as a BMI &lt;18.5",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      excluding subjects with illness-related weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/13\">",
"       13",
"      </a>",
"      ]. Being underweight was associated with excess mortality (33,746 excess deaths) in both smokers and nonsmokers [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link&amp;anchor=H7#H7\">",
"       \"Screening for and clinical evaluation of obesity in adults\", section on 'Classification of BMI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, a Nurses' Health Study report of over 115,000 women found that mortality was lowest in nonsmoking lean women (defined as weight at least 15 percent less than the United States average for women of similar age) with recently stable weight [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings, taken together, suggest that the association between a low BMI and increased mortality is probably, in part, an artifact of preexisting disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cause-specific mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between BMI and cause-specific mortality was illustrated in the Prospective Studies Collaboration analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/10\">",
"     10",
"    </a>",
"    ]. In the upper BMI range (25 to 50",
"    <span class=\"nowrap\">",
"     kg/m2),",
"    </span>",
"    each 5",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    increase in BMI was associated with a significant increase in mortality from each of the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic heart disease (hazard ratio [HR] 1.39) and stroke (HR 1.39)",
"     </li>",
"     <li>",
"      Diabetes (HR 2.16) and non-neoplastic chronic kidney disease (HR 1.59)",
"     </li>",
"     <li>",
"      Neoplastic disease (HR 1.10), with the association between BMI and mortality being significant for several types of cancer, including liver, kidney, breast, endometrial, prostate, and colon",
"     </li>",
"     <li>",
"      Respiratory diseases (HR 1.20)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overweight during adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Being overweight during adolescence may also increase the risk of premature death as an adult. This was illustrated in an analysis of the Nurses' Health Study where the risk of premature death increased with higher BMIs at age 18 years; for a BMI at age 18 of 18.5 to 21.9, 22 to 24.9, 25 to 29.9, and &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    the hazard ratio for premature death was 0.98, 1.18, 1.66, and 2.79, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/21\">",
"     21",
"    </a>",
"    ]. This association could only partly be explained by being overweight as an adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trends in cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NHANES study reported that although the prevalence of obesity (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    increased dramatically in the United States between 1960 and 2000 (15 to 30 percent), the impact of obesity on mortality decreased over time, thought to be related to a decrease in the prevalence of cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/13,22\">",
"     13,22",
"    </a>",
"    ]. As expected, there was an increase in diagnosed diabetes (1.8 to 5.0 percent) between 1960 and 2000 that was most prominent in obese subjects (2.9 to 10.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, the prevalence of other major cardiovascular risk factors declined substantially between 1960 and 2000:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum total cholesterol &ge;240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      &mdash; prevalence decreased from 34 to 17 percent",
"     </li>",
"     <li>",
"      Hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &ge;140/&ge;90",
"      </span>",
"      mmHg) &mdash; 31 to 15 percent",
"     </li>",
"     <li>",
"      Smoking &mdash; 39 to 26 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes occurred in all weight groups, including obese individuals, and were associated with increases in the use of lipid-lowering drugs and antihypertensive medications. As a result, the impact of obesity on mortality appeared to decrease over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the NHANES study also reported that these cardiovascular improvements have not been accompanied by reduced disability in the obese older population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/23\">",
"     23",
"    </a>",
"    ]. In fact, obese participants were more likely than the nonobese to report functional impairments over time.",
"   </p>",
"   <p>",
"    In contrast to the NHANES data, in an analysis based upon a much larger cohort followed for over 20 years, there was no evidence that the magnitude of the association between obesity and mortality had decreased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect of fitness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fitness level is also an important factor in obese individuals. In one study, higher levels of fitness appeared to negate some of the excess cardiovascular mortality risk associated with obesity in men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, in the Lipids Research Clinics and the Nurses' Health Studies, both physical fitness and adiposity were independent predictors of mortality, and higher levels of fitness did not negate the association between obesity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Life expectancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity in adulthood is also associated with a striking reduction in life expectancy for both men and women. Among 3457 subjects in the Framingham Study, those who were obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    at age 40 years lived six to seven years less than those who were not (BMI &le;24.9",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"    Those who were overweight (BMI 25 to 29.9",
"    <span class=\"nowrap\">",
"     km/m2)",
"    </span>",
"    at age 40 years lived about three years less, and those who were both obese and smoked lived 13 to 14 years less than normal-weight nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second study noted a similar reduction in life expectancy, particularly among younger adults. The impact of obesity on years of life lost (YLL) was greater for men than women and for whites than blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/29\">",
"     29",
"    </a>",
"    ]. Furthermore, in a model designed to estimate the joint effects of obesity and smoking cessation on longevity and quality of life, using data from NHANES I, II, III, and 2004 through 2006, the negative impact of obesity on life expectancy is forecasted to outweigh the health benefits of smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the steady rise in life expectancy during the past two centuries may come to an end because of the increasing prevalence of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity and increased central fat are associated with increased morbidity in addition to mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a survey of adults in the United States, overweight and obese individuals had a higher relative risk of hypertension, hypercholesterolemia, and diabetes mellitus, compared with normal weight individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/34\">",
"     34",
"    </a>",
"    ]. The risk of hypertension and diabetes increased with increasing BMI (adjusted odds ratios 2.6 to 4.8 [for hypertension] and 1.6 to 5.1 [for diabetes] in individuals with BMIs ranging from 25 to &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    Swedish Obese Subjects Study was a longitudinal study of obese individuals (mean BMI 41; mean age 48 years) who chose either bariatric surgery or conventional therapy for weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/35\">",
"     35",
"    </a>",
"    ]. At two years, patients in the conventional therapy group lost little weight, and the following percentages of subjects were affected by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension &mdash; 13.6 percent",
"     </li>",
"     <li>",
"      Diabetes mellitus &mdash; 6.3 percent",
"     </li>",
"     <li>",
"      Hyperinsulinemia &mdash; 6.3 percent",
"     </li>",
"     <li>",
"      Hypertriglyceridemia &mdash; 7.7 percent",
"     </li>",
"     <li>",
"      Low serum high-density-lipoprotein (HDL) cholesterol concentration &mdash; 8.6 percent",
"     </li>",
"     <li>",
"      Hypercholesterolemia &mdash; 12.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this study are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Nurses' Health and the Health Professionals Studies, the risk of developing a chronic disease (gallstones, hypertension, heart disease, colon cancer, and stroke [in men only]) increased with increasing BMI, even in those in the upper half of the healthy weight range (BMI 22.0 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. While these data suggest that a BMI &lt;22.0",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    would be ideal, this is a difficult and perhaps unrealistic goal for many individuals. In addition, the majority of subjects studied were Caucasian and, therefore, these data cannot be extrapolated to other ethnic groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes mellitus is strongly associated with obesity in all ethnic groups. More than 80 percent of cases of type 2 diabetes can be attributed to obesity, which may also account for many diabetes-related deaths.",
"   </p>",
"   <p>",
"    A curvilinear relationship between BMI and the risk of type 2 diabetes was found in women in the Nurses' Health Study (",
"    <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The lowest risk was associated with a BMI below 22",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (slightly lower than in men from the Health Professionals Study); at a BMI greater than 35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    the relative risk for diabetes adjusted for age increased to 61. The risk may be increased further by a sedentary lifestyle or decreased by exercise (",
"    <a class=\"graphic graphic_figure graphicRef79316 \" href=\"UTD.htm?7/3/7230\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to BMI, the distribution of body fat appears to be an important determinant of diabetes risk, as illustrated by the findings of a prospective population-based cohort study in which 732 obese adults were followed for a median of seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/40\">",
"     40",
"    </a>",
"    ]. Diabetes incidence increased significantly across tertiles of baseline waist circumference, waist-to-hip ratio, and excess visceral fat mass, whereas there was no association noted between diabetes incidence and total body or abdominal subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/40\">",
"     40",
"    </a>",
"    ]. Similar findings were previously noted in adults participating in the Third National Health and Nutrition Examination Survey, where individuals with high waist circumference values (men &gt;102 cm [40 inches], women &gt;88 cm [35 inches]) were more likely to have diabetes, hypertension, and dyslipidemia compared with those who had normal waist circumference values [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight gain after age 18 years in women and after age 20 years in men also increases the risk of type 2 diabetes. The Nurses' Health Study, for example, compared women with stable weight (those who gained or lost &lt;5 kg) after the age of 18 years to women who gained weight [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Those who had gained 5.0 to 7.9 kg had a relative risk of diabetes of 1.9; this risk increased to 2.7 for women who gained 8.0 to 10.9 kg (",
"    <a class=\"graphic graphic_figure graphicRef52842 \" href=\"UTD.htm?4/42/4783\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"     37",
"    </a>",
"    ]. Similar findings were noted in men in the Health Professionals Study (",
"    <a class=\"graphic graphic_figure graphicRef52842 \" href=\"UTD.htm?4/42/4783\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37,42\">",
"     37,42",
"    </a>",
"    ]. Thus, the excess risk for diabetes with even modest weight gain is substantial.",
"   </p>",
"   <p>",
"    Weight loss is associated with a decreased risk of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H12#H12\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Weight loss/lifestyle intervention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of type 2 diabetes may also be associated with specific dietary patterns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance with hyperinsulinemia is characteristic of obesity and is present before the onset of hyperglycemia. After the onset of obesity, the first demonstrable changes are impairment in glucose removal and increased insulin resistance, which result in hyperinsulinemia. The hyperinsulinemia in turn increases hepatic very-low-density triglyceride synthesis, plasminogen activator inhibitor-1 synthesis, sympathetic nervous system activity, and sodium reabsorption. These changes contribute to hyperlipidemia and hypertension in obese subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The insulin resistance characteristic of type 2 diabetes probably results from a combination of obesity and genetic factors. In a study of nondiabetic offspring of two parents with type 2 diabetes, for example, insulin sensitivity was similar to that of normal subjects with no first-degree relatives with type 2 diabetes at near ideal body weight; at increasing degrees of obesity, however, the progressive decrease in insulin sensitivity was much more pronounced in those with a family history of type 2 diabetes (",
"    <a class=\"graphic graphic_figure graphicRef70645 \" href=\"UTD.htm?32/37/33373\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/44\">",
"     44",
"    </a>",
"    ]. It is not entirely clear how obesity induces insulin resistance, but a number of mechanisms may be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure is often increased in obese subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/34\">",
"     34",
"    </a>",
"    ], although as noted above, the prevalence of obesity-associated hypertension may be decreasing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Swedish Obesity Study hypertension was present at baseline in approximately one-half of subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the Nurses' Health Study, the BMI at age 18 years and at midlife was positively associated with the occurrence of hypertension (",
"      <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"       37",
"      </a>",
"      ]. Weight gain was also associated with an increased risk; the relative risk of hypertension in those women who gained 5.0 to 9.9 kg and &ge;25.0 kg was 1.7 and 5.2, respectively (",
"      <a class=\"graphic graphic_figure graphicRef52842 \" href=\"UTD.htm?4/42/4783\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"       37",
"      </a>",
"      ]. Similar findings were noted in men in the Health Professionals Study (",
"      <a class=\"graphic graphic_figure graphicRef52842 \" href=\"UTD.htm?4/42/4783\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37,42\">",
"       37,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review from the Framingham Heart Study, in which participants were prospectively followed for up to 44 years, estimated that excess body weight (including overweight and obesity) could account for up to 26 percent of cases of hypertension in men and 28 percent in women [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of hypertension is greatest in those subjects with upper body and abdominal obesity. The mechanism by which upper body obesity raises blood pressure is poorly understood. One theory proposes a central role for insulin resistance, leading to impaired glucose tolerance and hyperinsulinemia. Hyperinsulinemia may then raise the blood pressure by increasing sympathetic activity, renal sodium reabsorption, or vascular tone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link&amp;anchor=H3#H3\">",
"     \"Obesity and weight reduction in hypertension\", section on 'Hyperinsulinemia and insulin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight loss in obese subjects is associated with a decline in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/46\">",
"     46",
"    </a>",
"    ]. For each 1 kg of weight loss, the systolic and diastolic blood pressures falls by approximately 1 mmHg&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef60178 \" href=\"UTD.htm?24/34/25133\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/47\">",
"     47",
"    </a>",
"    ]. On the other hand, persistent obesity not only raises the blood pressure directly, but also makes the hypertension more difficult to control by interfering with the efficacy of antihypertensive drugs. The effect of weight loss in obese patients with hypertension is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link&amp;anchor=H6#H6\">",
"     \"Obesity and weight reduction in hypertension\", section on 'Effects of weight reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with several deleterious changes in lipid metabolism although, as noted above, the prevalence of obesity-associated dyslipidemia may be decreasing. Unfavorable obesity-related effects include high serum concentrations of cholesterol, low-density-lipoprotein (LDL) cholesterol, very-low-density-lipoprotein (VLDL) cholesterol, and triglycerides, and a reduction in serum high-density-lipoprotein (HDL) cholesterol of about 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/48\">",
"     48",
"    </a>",
"    ]. The last effect may be most important since a low serum HDL cholesterol concentration carries a greater relative risk of coronary heart disease (CHD) than hypertriglyceridemia.",
"   </p>",
"   <p>",
"    Central fat distribution also plays an important role in the serum lipid abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing gouty arthritis increases with body weight and with the amount of weight gain during adulthood. The influence of body mass index (BMI) on hyperuricemia and gout is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with a number of risk factors for cardiovascular disease, including hypertension, insulin resistance and diabetes mellitus, dyslipidemia, high plasma fibrinogen concentrations and other prothrombotic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/49\">",
"     49",
"    </a>",
"    ], and in women with central obesity, an increase in thromboxane-dependent platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity is also associated with increased risks of coronary disease, heart failure and, as described above, cardiovascular and all-cause mortality. Weight loss (if achieved through lifestyle interventions, medication, or surgery) is associated with an improvement in cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/51\">",
"     51",
"    </a>",
"    ]. However, liposuction of large amounts of abdominal fat does not appear to improve cardiovascular risk profiles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3641?source=see_link\">",
"     \"Obesity, weight reduction, and cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of therapy for obesity in adults\", section on 'Liposuction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has been associated with an increased risk of coronary heart disease (CHD) and cardiovascular mortality in many observational studies, including the Framingham Heart Study and the Nurses' Health Study (",
"    <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37,45,48\">",
"     37,45,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the increase in CHD risk is most pronounced with obesity, it is also seen with increasing weight within the \"normal\" range:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a BMI less than 21",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      as a reference in the Nurses' Health Study, the adjusted relative risk for CHD was 1.19 at a BMI of 21 to 22.9",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      1.46 at 23 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      2.06 at 25 to 28.9",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      (considered overweight but not obese), and 3.56 at a BMI &ge;29",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the Framingham Heart Study, excess body weight (including overweight and obesity) accounted for approximately 23 percent of cases of CHD in men and 15 percent in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distribution of body fat appears to be an important determinant as patients with abdominal (central) obesity are at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the INTERHEART study of patients from 52 countries, abdominal obesity accounted for 20 percent of the population attributable risk of a first MI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of CHD appears to rise steeply with a waist-to-hip ratio [WHR] above 0.8 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/56\">",
"       56",
"      </a>",
"      ]. In one report, women with a WHR &ge;0.88 are at significantly higher risk of CHD when compared with women with a WHR &le;0.72 (RR 3.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/57\">",
"       57",
"      </a>",
"      ]. In addition, a waist circumference of &ge;96.5 cm (38 in) was independently associated with CHD risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adverse cardiovascular effects of obesity may be seen at a relatively young age. As an example, in an autopsy study of 3000 subjects under age 35 years (who had died of external causes), increasing BMI was associated with fatty streaks and raised atherosclerotic lesions in the right and left anterior descending coronary arteries in young men (but not young women) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/52\">",
"     52",
"    </a>",
"    ]. In a second, retrospective study of 189,065 patients with acute coronary syndrome, increasing BMI was associated with premature age at first non-ST-segment elevation myocardial infarction (mean age 75 and 59 years for the leanest (BMI &le;18 5",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    and most obese (BMI &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    cohorts, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The excess risk of CHD in obese patients may be related to low serum concentrations of adiponectin, an adipocyte-derived cytokine, which has insulin-sensitizing and anti-atherogenic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Adiponectin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that, although obesity is a risk factor for developing CHD, it may also be associated with better outcomes after non-ST-segment elevation myocardial infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, the improved outcomes appear to be explained by the more aggressive inpatient management that the obese patients received [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/60\">",
"     60",
"    </a>",
"    ]. It is also possible that post-MI outpatient management was more aggressive in the obese patients, but this was not addressed in either study. In a third trial, the \"obesity paradox\" (the inverse relationship between BMI and mortality after myocardial infarction) was related to confounding by differences in baseline characteristics (such as age, sex) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 21 cohort studies suggests that the adverse effects of obesity on blood pressure and lipids accounts for approximately one-half of the excess risk of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/63\">",
"     63",
"    </a>",
"    ]. However, after correction for these and other risk factors, overweight and obesity were still associated with an increased risk of CHD (RR 1.17 and 1.49, respectively). Similar findings were noted in an analysis by the Emerging Risk Factors Collaboration that used individual patient data from 58 European and US cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/64\">",
"     64",
"    </a>",
"    ]. In adults with a BMI &ge;20",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    BMI, waist circumference, and waist-to-hip ratio were similarly associated with cardiovascular risk (HR for every standard deviation increase in BMI, waist circumference, and waist-to-hip ratio 1.23, 1.26, and 1.25, respectively). The association between BMI, waist circumference, waist-to-hip ratio, and CHD was attenuated (HR 1.11 to 1.14) after adjustment for blood pressure, history of diabetes, and total and HDL cholesterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an important association between obesity and heart failure. In an analysis from the Framingham Heart Study in which almost 6000 individuals without a history of heart failure (mean age 55 years) were followed for a mean of 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/65\">",
"     65",
"    </a>",
"    ], heart failure developed in 496 (8.4 percent). The risk of heart failure was increased approximately twofold in obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    compared with nonobese subjects. After adjusting for established risk factors (eg, hypertension, coronary disease, diabetes, left ventricular hypertrophy), the risk of heart failure increased 5 percent in men and 7 percent in women for each increment of 1",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    in BMI. Approximately 11 percent of cases of heart failure in men and 14 percent in women could be attributed to obesity alone. The risk was also increased in overweight (BMI 25 to 29.9",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    women but not men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a number of mechanisms by which obesity could predispose to heart failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity is associated with several changes in cardiovascular function, some of which increase cardiac work (",
"      <a class=\"graphic graphic_table graphicRef74883 \" href=\"UTD.htm?42/31/43516\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/48,51,66\">",
"       48,51,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac weight increases with increasing body weight, a change that is reversible, being proportionate to the degree of weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increased risk of heart failure with obesity may be mediated by insulin resistance. This was illustrated in a prospective, cohort study of 1187 elderly men free of heart failure at baseline. In a multivariate analysis adjusted for established risk factors for heart failure (diabetes, prior MI, hypertension, LVH, smoking, and dyslipidemia), independent predictors of subsequent heart failure included higher BMI, waist circumference, fasting serum proinsulin levels, two-hour blood glucose concentrations, and insulin resistance (lower glucose disposal rate measured by a euglycemic clamp study). When glucose disposal rate was then added as a covariate, BMI and waist circumference were no longer independent predictors, suggesting that insulin resistance may mediate the increased risk of heart failure seen with obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overweight and obesity may also be associated with subclinical right ventricular dysfunction, independent of obstructive sleep apnea, diabetes, mellitus, and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Myocardial steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One potential mechanism for heart disease in obesity is thought to be excessive lipid accumulation in the myocardium. In rodent models, myocardial steatosis appears to cause left ventricular hypertrophy and nonischemic dilated cardiomyopathy. Studies in healthy subjects or patients with heart failure (using magnetic resonance spectroscopy) suggest that myocardial triglyceride content increases with increasing BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/69\">",
"     69",
"    </a>",
"    ]. The increasing adiposity of the heart may contribute directly to the structural (left ventricular hypertrophy) and functional (hyperdynamic circulation) cardiac adaptations seen with obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     ECG in morbid obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbid obesity can cause changes in cardiac morphology that can alter the surface ECG. One study compared the ECGs of 100 obese subjects and 100 normal subjects; none of the subjects had any evidence of cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/70\">",
"     70",
"    </a>",
"    ]. Compared with the normal subjects, the obese subjects had the following alterations on the ECG:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The P, QRS, and T wave axes were more leftward",
"     </li>",
"     <li>",
"      Multiple ECG criteria for left ventricular hypertrophy and left atrial abnormality and T wave flattening in the inferior and lateral leads were more common",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prolonged QT interval (which improves with weight loss) has also been reported in obese individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Atrial fibrillation/flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese individuals (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    are significantly more likely to develop atrial fibrillation than those with a normal BMI (&lt;25",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. This was illustrated in an analysis from the Framingham study of 5282 patients without AF at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/73\">",
"     73",
"    </a>",
"    ]. Body mass index (BMI) was determined for all participants. At a mean follow-up of 14 years, 526 patients (10 percent) developed AF. Obese participants (BMI &ge;30) were significantly more likely to develop AF than those with a normal BMI (&lt;25) (adjusted HR 1.52 for men and 1.46 for women). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another population-based prospective cohort study of 47,589 men and women without preexisting cardiovascular disease, obese individuals (BMI &ge;30) were at increased risk for developing either atrial fibrillation or flutter when compared with normal weight individuals (BMI &lt;25) (HR 2.35 in men; 1.99 in women) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/74\">",
"     74",
"    </a>",
"    ]. The association with BMI appears to be stronger for sustained atrial fibrillation when compared with transient or intermittent atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Nurses' Health Study found that both an increased BMI (&ge;27",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    and weight gain after age 18 years were associated with an increased risk of ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/77\">",
"     77",
"    </a>",
"    ]. The relative risk was 1.8 for a BMI of 27 to 28.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    1.9 for a BMI of 29 to 31.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    and 2.4 for a BMI of 32",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    or more as compared with a BMI of less than 21",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    A similar increase in ischemic stroke was noted in the Women's Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/78\">",
"     78",
"    </a>",
"    ]. In the Nurses' Health Study, weight gain of 11 to 19.9 kg after age 18 years was associated with a relative risk of ischemic stroke of 1.7, while those women with a gain of 20 kg or more had a relative risk of 2.5 compared with those who had stable weight (loss or gain &lt;5 kg). Neither BMI nor weight gain was associated with an increase in the risk of hemorrhagic stroke, although the relationship persisted for total stroke risk.",
"   </p>",
"   <p>",
"    In men, increasing BMI was associated with an increased risk of both ischemic and hemorrhagic stroke in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/79\">",
"     79",
"    </a>",
"    ] and with total and ischemic (but not hemorrhagic) in another [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis by the Emerging Risk Factors Collaboration of 21 studies (over 85,000 participants) found that the risk of ischemic stroke significantly increased for every one standard deviation increase in BMI, waist circumference, and waist-to-hip ratio (HR 1.20, 1.25, and 1.25, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/64\">",
"     64",
"    </a>",
"    ]. After adjustment for age, gender, smoking status, blood pressure, history of diabetes, and total and HDL cholesterol, the risk was markedly attenuated (HR 1.06 to 1.14).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has been associated with an increased risk of deep vein thrombosis and pulmonary embolus. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H52#H52\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity may be associated with an increased risk of later dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk factors for dementia\", section on 'Lifestyle and activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hepatobiliary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity affects the hepatobiliary system, primarily by causing cholelithiasis. This has been demonstrated in many studies. In the Nurses' Health Study, women with a BMI &lt;24",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    had an incidence of symptomatic gallstones of approximately 250 per 100,000 person-years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/81\">",
"     81",
"    </a>",
"    ]. There was a gradual increase in incidence rate with increasing BMI, beginning at the upper half of the normal range (",
"    <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"     37",
"    </a>",
"    ]. Similar findings were noted in men in the Health Professionals Study (",
"    <a class=\"graphic graphic_figure graphicRef76866 \" href=\"UTD.htm?12/22/12655\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of gallstones in obese subjects is in part explained by increased production and biliary excretion of cholesterol. Cholesterol production is linearly related to body fat with approximately 20 mg of additional cholesterol being synthesized daily for each kg of extra body fat. Thus, a 10 kg increase in body fat leads to the daily synthesis of the amount of cholesterol that is contained in the yolk of one egg. The excess cholesterol is excreted in the bile. High biliary concentrations of cholesterol relative to bile acids and phospholipids increase the likelihood of precipitation of cholesterol within the gallbladder.",
"   </p>",
"   <p>",
"    Weight loss may also increase the likelihood of cholelithiasis since the flux of cholesterol through the biliary system increases. Diets with moderate amounts of fat that trigger gallbladder contraction may reduce this risk. Similarly, therapy with a bile acid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    ) may be advisable in selected subjects (eg, subjects who are losing weight rapidly: &gt;1 to 1.5",
"    <span class=\"nowrap\">",
"     kg/week).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The quantity of fat in the liver may also be increased in obese subjects. Steatosis is a common abnormality seen on liver biopsy; it is due to the deposition of triglycerides in hepatocytes in the form of lipid droplets. In obese subjects, excess triglycerides may be produced due to increased peripheral lipolysis. Triglycerides are normally packaged into VLDL; if, however, the rate of triglyceride synthesis exceeds the rate of clearance, the excess accumulates in the liver. Steatosis resolves with weight loss, except after intestinal bypass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16073?source=see_link\">",
"     \"Pathogenesis of nonalcoholic fatty liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     GERD/GI cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a risk factor for GERD, erosive esophagitis, esophageal adenocarcinoma, and gastric cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk factors for gastric cancer\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of osteoarthritis is increased in obese subjects, and accounts for a major component of the cost of obesity. Osteoarthritis commonly develops in the knees and ankles; this may be directly related to the trauma associated with excess body weight. However, it also occurs more frequently in non-weight-bearing joints, suggesting that there are components of the obesity syndrome that alter cartilage and bone metabolism independent of weight-bearing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of over 1000 women, obesity was classified as the upper tertile of BMI; the boundaries of the middle tertile were 23.4 and 26.4",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    The age-adjusted odds ratios of unilateral and bilateral osteoarthritis at the knee, determined from x-rays of the knees, comparing the high and low tertiles of BMI were 6.2 and 18, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/83\">",
"     83",
"    </a>",
"    ]. Comparing the middle and low tertile of BMI, the odds ratios for osteoarthritis at various joints were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Knee &mdash; 2.9",
"     </li>",
"     <li>",
"      Carpometacarpal joint &mdash; 1.7",
"     </li>",
"     <li>",
"      Distal interphalangeal joint &mdash; 1.5",
"     </li>",
"     <li>",
"      Proximal interphalangeal joint &mdash; 1.2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A twin study found similar results; each kilogram increase in body weight (compared with a twin control) was associated with an increased risk of radiographic features of osteoarthritis at the knee and carpometacarpal joint [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, weight loss is associated with a decreased risk of osteoarthritis. In a study of 800 women a decrease in BMI of 2",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    or more in the preceding 10 years decreased the odds for developing osteoarthritis by over 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/85\">",
"     85",
"    </a>",
"    ]. This benefit was also found among those women with a high risk for osteoarthritis due to a high baseline BMI (&ge;25",
"    <span class=\"nowrap\">",
"     kg/m2).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Skin changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several changes in the skin are associated with obesity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stretch marks (striae) are common and reflect the tension on the skin from expanding subcutaneous deposits of fat.",
"     </li>",
"     <li>",
"      Acanthosis nigricans, with deepening pigmentation around the neck, axilla (",
"      <a class=\"graphic graphic_picture graphicRef53776 \" href=\"UTD.htm?3/7/3198\">",
"       picture 1",
"      </a>",
"      ), knuckles and extensor surfaces, may occur in connection with obesity. While this skin condition has been associated with cancer in some patients (eg, gastric cancer), it is",
"      <strong>",
"       not",
"      </strong>",
"      related to an increased risk of cancer in obese subjects. The proposed cause of this lesion is sustained hyperinsulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/86\">",
"       86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"       \"Insulin resistance: Definition and clinical spectrum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hirsutism in women may result from increased production of testosterone, which is often associated with visceral obesity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=see_link\">",
"       \"Pathogenesis and causes of hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Respiratory system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep apnea is the most important respiratory problem associated with obesity and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/87\">",
"     87",
"    </a>",
"    ], with several studies confirming that obesity is a major risk factor for the development of obstructive sleep apnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other alterations in pulmonary function may occur, including higher residual lung volume associated with increased abdominal pressure on the diaphragm, decreased lung compliance and increased chest wall impedance, ventilation-perfusion abnormalities, reduced strength and endurance of respiratory muscles, depressed ventilatory drive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/88\">",
"     88",
"    </a>",
"    ], and bronchospasm (asthma) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=see_link\">",
"     \"Pathogenesis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity has been thought to be a risk factor for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/90,91\">",
"     90,91",
"    </a>",
"    ], but in one cohort study obesity was associated with dyspnea, but not asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H22#H22\">",
"     \"Risk factors for asthma\", section on 'Obesity'",
"    </a>",
"    .) These effects on respiratory function are considered to be relatively benign or uncommon, compared with the problems induced by obesity-associated hypoventilation or obstructive sleep apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain forms of cancer occur with increased frequency in obese men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. Obesity also increases the likelihood of dying from cancer. In a prospective cohort study of over 900,000 adults (404,576 men and 495,477 women) in the US followed for 16 years (1982 to 1998), the following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both men and women with a BMI greater than 40",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      had a higher risk of death from cancer than normal weight subjects (BMI 18.5 to 24.9; RR 1.5, 95% CI 1.1-2.0 and RR 1.6, 95% CI 1.4-1.9, for men and women, respectively).",
"     </li>",
"     <li>",
"      For both men and women, increasing BMI was associated with higher death rates due to the following cancers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Esophagus",
"     </li>",
"     <li>",
"      Colon and rectum",
"     </li>",
"     <li>",
"      Liver",
"     </li>",
"     <li>",
"      Gallbladder",
"     </li>",
"     <li>",
"      Pancreas",
"     </li>",
"     <li>",
"      Kidney",
"     </li>",
"     <li>",
"      Non-Hodgkin lymphoma",
"     </li>",
"     <li>",
"      Multiple myeloma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Men were also at increased risk of death from stomach and prostate cancer, while women were at increased risk of death from cancers of the breast, uterus, cervix, and ovary. Based upon these associations, the authors calculated that overweight and obesity in the US could account for 14 percent of all cancer deaths in men, and 20 percent of those in women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 141 studies that included 282,137 cancer cases, a 5",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    increase in BMI in men was associated with esophageal, thyroid, colon, and renal cancers (RR 1.52, 1.33, 1.24, and 1.24, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/97\">",
"     97",
"    </a>",
"    ]. In women, a 5",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    increase was associated with endometrial, gallbladder, esophageal, and renal cancers (RR 1.59, 1.59, 1.51, and 1.34, respectively). Associations were similar in studies from North America, Europe, Australia, and the Asia-Pacific region, with the exception of stronger associations between BMI and breast cancer in the Asia-Pacific populations.",
"   </p>",
"   <p>",
"    The relationship between obesity and risk of breast, endometrial, colon, and prostate cancer are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H843677#H843677\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H13#H13\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link&amp;anchor=H24#H24\">",
"     \"Risk factors for prostate cancer\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Endocrine changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the changes noted above (diabetes and hyperlipidemia), several other endocrine changes are associated with obesity. Irregular menses and anovulatory cycles are common in obese women, and fertility may be decreased. There are also reports of an increased risk of pregnancy-induced hypertension, and cesarean delivery may be more frequent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders of sexual arousal and orgasm may be more common in overweight and obese [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men, obesity is an independent risk factor for erectile dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with multiple other conditions that are known to cause compromised renal function, including hypertension, diabetes, and the metabolic syndrome. However, data from the Framingham Offspring study, the Hypertension Detection and Follow-Up Program, and the Multiphasic Health Testing Services Program suggest that obesity may be independently associated with the risk of developing chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/99-102\">",
"     99-102",
"    </a>",
"    ]. Focal segmental glomerulosclerosis and obesity-related glomerulopathy (glomerular enlargement and mesangial expansion), both of which are associated with proteinuria, have been described in patients with severe obesity. Obesity-related glomerulopathy may be reversible with weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=see_link\">",
"     \"Epidemiology of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Kidney stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity and weight gain during adulthood appear to be associated with an increased risk of kidney stones [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women, overweight and obesity are important risk factors for urinary incontinence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, risk factors, and pathogenesis of urinary incontinence\", section on 'Risk factors and contributing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Psychosocial function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese subjects are often exposed to public disapproval because of their fatness. This stigma is seen in education, employment, and health care, among other areas. In a study of over 10,000 adolescents, women who were overweight (defined as a BMI above the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and sex) completed fewer years of school (0.3 year less), were less likely to be married (20 percent less likely), had lower household incomes ($6710 less per year), and had higher rates of household poverty (10 percent higher) than the women who had not been overweight, independent of their baseline socioeconomic status and aptitude test scores [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/104\">",
"     104",
"    </a>",
"    ]. Men who had been overweight were less likely to be married (11 percent less likely).",
"   </p>",
"   <p>",
"    Depression has also been seen in association with severe obesity, particularly in younger patients and in women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     COST OF OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Swedish Obesity Study obese subjects had 1.4 to 2.4 times the number of days of sick leave as did normal-weight subjects and were 1.5 to 2.8 times as likely to draw a disability pension. In addition, yearly drug costs were significantly higher in obese compared with normal-weight people [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/106\">",
"     106",
"    </a>",
"    ]. Surgical treatment for obesity lowered diabetes and cardiovascular disease-related drug costs, but increased gastrointestinal drug costs, resulting in similar total drug costs for surgically and conventionally treated obese patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other reports have found an increase in health care expenditures among overweight subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/35/30266/abstract/33,107-110\">",
"     33,107-110",
"    </a>",
"    ]. In one study, subjects at the extremes of BMI had the highest expenditures, while those in the middle of the BMI range (26 to 27",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    had the lowest probability of using health care dollars. In a second review of over 17,000 people in a health maintenance organization, there was an association between BMI and annual rates of days of hospitalization, number and costs of outpatient visits, costs of outpatient pharmacy and laboratory services, and total costs. Specifically, mean annual total costs were 25 percent greater among subjects with a BMI 30 to 34.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    relative to a BMI of 20 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    and 44 percent greater among those with a BMI of 35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    or higher. The higher costs were predominantly explained by the presence of CHD, hypertension, and diabetes. Similar data have been presented in the Netherlands and France.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       \"Patient information: Weight loss treatments (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=see_link\">",
"       \"Patient information: Health risks of obesity (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=see_link\">",
"       \"Patient information: Weight loss surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity is associated with significant excess morbidity and mortality. Estimates for annual obesity-associated mortality are extremely variable (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Mortality'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Obesity and increased central fat are associated with increased morbidity, including diabetes mellitus, hypertension, and heart disease, stroke, sleep apnea, and many others. Weight loss will improve most of these morbidities (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Morbidity'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Intentional weight loss is also associated with a reduction in overall mortality, mortality from myocardial infarction, and stroke, and a reduced incidence of cancer. The management of obesity is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bray GA. The Battle of the Bulge: A History of Obesity Research, Dorrance, Pittsburgh 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/2\">",
"      Yan LL, Daviglus ML, Liu K, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006; 295:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/3\">",
"      Gu D, He J, Duan X, et al. Body weight and mortality among men and women in China. JAMA 2006; 295:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/4\">",
"      Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/5\">",
"      Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/6\">",
"      McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 2006; 296:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/7\">",
"      Freedman DM, Ron E, Ballard-Barbash R, et al. Body mass index and all-cause mortality in a nationwide US cohort. Int J Obes (Lond) 2006; 30:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/8\">",
"      Price GM, Uauy R, Breeze E, et al. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. Am J Clin Nutr 2006; 84:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/9\">",
"      Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/10\">",
"      Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/11\">",
"      Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/12\">",
"      Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Correction: actual causes of death in the United States, 2000. JAMA 2005; 293:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/13\">",
"      Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/14\">",
"      Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/15\">",
"      Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/16\">",
"      Boggs DA, Rosenberg L, Cozier YC, et al. General and abdominal obesity and risk of death among black women. N Engl J Med 2011; 365:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/17\">",
"      Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 2011; 364:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/18\">",
"      Widlansky ME, Sesso HD, Rexrode KM, et al. Body mass index and total and cardiovascular mortality in men with a history of cardiovascular disease. Arch Intern Med 2004; 164:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/19\">",
"      Mark DH. Deaths attributable to obesity. JAMA 2005; 293:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/20\">",
"      Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/21\">",
"      van Dam RM, Willett WC, Manson JE, Hu FB. The relationship between overweight in adolescence and premature death in women. Ann Intern Med 2006; 145:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/22\">",
"      Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/23\">",
"      Alley DE, Chang VW. The changing relationship of obesity and disability, 1988-2004. JAMA 2007; 298:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/24\">",
"      Calle EE, Teras LR, Thun MJ. Obesity and mortality. N Engl J Med 2005; 353:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/25\">",
"      Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999; 69:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/26\">",
"      Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002; 156:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/27\">",
"      Hu FB, Willett WC, Li T, et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/28\">",
"      Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003; 138:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/29\">",
"      Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003; 289:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/30\">",
"      Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med 2009; 361:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/31\">",
"      Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/32\">",
"      Haslam DW, James WP. Obesity. Lancet 2005; 366:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/33\">",
"      Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/34\">",
"      Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/35\">",
"      Sj&ouml;str&ouml;m L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/36\">",
"      Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/37\">",
"      Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/38\">",
"      Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/39\">",
"      Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/40\">",
"      Neeland IJ, Turer AT, Ayers CR, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012; 308:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/41\">",
"      Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med 2002; 162:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/42\">",
"      Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/43\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/44\">",
"      Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994; 43:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/45\">",
"      Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/46\">",
"      Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/47\">",
"      Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/48\">",
"      Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/49\">",
"      Rosito GA, D'Agostino RB, Massaro J, et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/50\">",
"      Dav&igrave; G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/51\">",
"      Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110:2952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/52\">",
"      McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002; 105:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/53\">",
"      Iribarren C, Darbinian JA, Lo JC, et al. Value of the sagittal abdominal diameter in coronary heart disease risk assessment: cohort study in a large, multiethnic population. Am J Epidemiol 2006; 164:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/54\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/55\">",
"      Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/56\">",
"      Bj&ouml;rntorp P. Regional patterns of fat distribution. Ann Intern Med 1985; 103:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/57\">",
"      Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/58\">",
"      Madala MC, Franklin BA, Chen AY, et al. Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008; 52:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/59\">",
"      Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/60\">",
"      Diercks DB, Roe MT, Mulgund J, et al. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. Am Heart J 2006; 152:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/61\">",
"      Buettner HJ, Mueller C, Gick M, et al. The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J 2007; 28:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/62\">",
"      Zeller M, Steg PG, Ravisy J, et al. Relation between body mass index, waist circumference, and death after acute myocardial infarction. Circulation 2008; 118:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/63\">",
"      Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007; 167:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/64\">",
"      Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; 377:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/65\">",
"      Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/66\">",
"      Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993; 306:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/67\">",
"      Ingelsson E, Sundstr&ouml;m J, Arnl&ouml;v J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/68\">",
"      Wong CY, O'Moore-Sullivan T, Leano R, et al. Association of subclinical right ventricular dysfunction with obesity. J Am Coll Cardiol 2006; 47:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/69\">",
"      McGavock JM, Victor RG, Unger RH, et al. Adiposity of the heart, revisited. Ann Intern Med 2006; 144:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/70\">",
"      Alpert MA, Terry BE, Cohen MV, et al. The electrocardiogram in morbid obesity. Am J Cardiol 2000; 85:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/71\">",
"      Pontiroli AE, Pizzocri P, Saibene A, et al. Left ventricular hypertrophy and QT interval in obesity and in hypertension: effects of weight loss and of normalisation of blood pressure. Int J Obes Relat Metab Disord 2004; 28:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/72\">",
"      Papaioannou A, Michaloudis D, Fraidakis O, et al. Effects of weight loss on QT interval in morbidly obese patients. Obes Surg 2003; 13:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/73\">",
"      Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/74\">",
"      Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 2005; 118:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/75\">",
"      Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006; 166:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/76\">",
"      Tedrow UB, Conen D, Ridker PM, et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 2010; 55:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/77\">",
"      Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/78\">",
"      Kurth T, Gaziano JM, Rexrode KM, et al. Prospective study of body mass index and risk of stroke in apparently healthy women. Circulation 2005; 111:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/79\">",
"      Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/80\">",
"      Hu G, Tuomilehto J, Silventoinen K, et al. Body mass index, waist circumference, and waist-hip ratio on the risk of total and type-specific stroke. Arch Intern Med 2007; 167:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/81\">",
"      Stampfer MJ, Maclure KM, Colditz GA, et al. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 1992; 55:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/82\">",
"      Grotle M, Hagen KB, Natvig B, et al. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord 2008; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/83\">",
"      Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: the Chingford Study. J Rheumatol 1993; 20:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/84\">",
"      Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol 1996; 23:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/85\">",
"      Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992; 116:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/86\">",
"      Rogers DL. Acanthosis nigricans. Semin Dermatol 1991; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/87\">",
"      Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009; 32:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/88\">",
"      Kress JP, Pohlman AS, Alverdy J, Hall JB. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med 1999; 160:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/89\">",
"      Ray CS, Sue DY, Bray G, et al. Effects of obesity on respiratory function. Am Rev Respir Dis 1983; 128:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/90\">",
"      Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/91\">",
"      Young SY, Gunzenhauser JD, Malone KE, McTiernan A. Body mass index and asthma in the military population of the northwestern United States. Arch Intern Med 2001; 161:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/92\">",
"      Sin DD, Jones RL, Man SF. Obesity is a risk factor for dyspnea but not for airflow obstruction. Arch Intern Med 2002; 162:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/93\">",
"      Pan SY, Johnson KC, Ugnat AM, et al. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004; 159:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/94\">",
"      Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 2005; 93:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/95\">",
"      Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/96\">",
"      Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/97\">",
"      Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/98\">",
"      Esposito K, Giugliano F, Ciotola M, et al. Obesity and sexual dysfunction, male and female. Int J Impot Res 2008; 20:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/99\">",
"      Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005; 46:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/100\">",
"      Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/101\">",
"      Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/102\">",
"      Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol 2007; 2:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/103\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/104\">",
"      Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 1993; 329:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/105\">",
"      Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003; 163:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/106\">",
"      Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/107\">",
"      Daviglus ML, Liu K, Yan LL, et al. Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA 2004; 292:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/108\">",
"      Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158:466.",
"     </a>",
"    </li>",
"    <li>",
"     International Obesity Task Force: Managing the global epidemic of obesity: a report of the International Obesity Task Force (Unpublished document).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/35/30266/abstract/110\">",
"      Finkelstein EA, Trogdon JG, Brown DS, et al. The lifetime medical cost burden of overweight and obesity: implications for obesity prevention. Obesity (Silver Spring) 2008; 16:1843.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5370 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30266=[""].join("\n");
var outline_f29_35_30266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cause-specific mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overweight during adolescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trends in cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect of fitness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Life expectancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Coronary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Myocardial steatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - ECG in morbid obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Atrial fibrillation/flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hepatobiliary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GERD/GI cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Skin changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Respiratory system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Endocrine changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Kidney disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Kidney stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Psychosocial function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      COST OF OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5370\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5370|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/2/7200\" title=\"figure 1\">",
"      Obesity all-cause mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/22/12655\" title=\"figure 2\">",
"      Rel risk disease BMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/3/7230\" title=\"figure 3\">",
"      Type2 DM weight and exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/42/4783\" title=\"figure 4\">",
"      Rel risk disease increase wt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/37/33373\" title=\"figure 5\">",
"      Obesity family hx and NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/34/25133\" title=\"figure 6\">",
"      Weight loss and fall in BP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5370|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/7/3198\" title=\"picture 1\">",
"      Acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5370|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/31/43516\" title=\"table 1\">",
"      Cardiac alterations in obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/521?source=related_link\">",
"      Epidemiology of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=related_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3641?source=related_link\">",
"      Obesity, weight reduction, and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16073?source=related_link\">",
"      Pathogenesis of nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21541?source=related_link\">",
"      Pathogenesis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=related_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/37/9811?source=related_link\">",
"      Patient information: Weight loss surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_35_30267="Bullous drug eruptions";
var content_f29_35_30267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bullous drug eruptions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug eruption",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Linear IgA bullous dermatosis",
"        </strong>",
"       </td>",
"       <td>",
"        Annular erythema and blisters (\"crown of jewels\").",
"       </td>",
"       <td>",
"        Vancomycin, penicillin, cephalosporins, ACE inhibitors, NSAIDs",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Pseudoporphyria",
"        </strong>",
"       </td>",
"       <td>",
"        Photodistributed blisters on dorsal hands, forearms, face. Similar clinical presentation as porphyria cutanea tarda (with negative porphyrin studies).",
"       </td>",
"       <td>",
"        NSAIDs, tetracyclines, furosemide",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Fixed drug eruption",
"        </strong>",
"       </td>",
"       <td>",
"        Dusky violaceous patch. Hemorrhagic vesicle or bulla. History of recurrences at same location with medication usage.",
"       </td>",
"       <td>",
"        Sulfonamides, NSAIDs, tetracyclines",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Stevens-Johnson syndrome, toxic epidermal necrolysis",
"        </strong>",
"       </td>",
"       <td>",
"        Widespread dusky erythema with epidermal detachment and flaccid blisters. Prominent mucosal involvement.",
"       </td>",
"       <td>",
"        Antibiotics, anticonvulsants, allopurinol, dapsone, NSAIDs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NSAIDs: Nonsteroidal antiinflammatory drugs",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30267=[""].join("\n");
var outline_f29_35_30267=null;
var title_f29_35_30268="Non-disease specific baseline guidelines for hospice";
var content_f29_35_30268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medical guidelines for determining appropriateness of hospice referral: Non-disease specific baseline guidelines plus comorbidities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A patient will be considered to have a life expectancy of six months and be eligible for hospice services if he/she meets criteria for BOTH the following non-disease specific baseline guidelines AND disease-specific guidelines (shown on a separate table)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Both A and B should be met:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A. Physiologic impairment of functional status as demonstrated by Karnofsky Performance Status (KPS) or Palliative Performance Score (PPS) &lt;70 percent. Note that two of the disease specific guidelines (HIV and stroke/coma) establish a lower qualifying KPS or PPS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        B. Dependence on assistance for two or more activities of daily living (ADLs)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent2\">",
"        <ol>",
"         <li>",
"          Feeding",
"         </li>",
"         <li>",
"          Ambulation",
"         </li>",
"         <li>",
"          Continence",
"         </li>",
"         <li>",
"          Transfer",
"         </li>",
"         <li>",
"          Bathing",
"         </li>",
"         <li>",
"          Dressing",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Although not the primary hospice diagnosis, the presence of comorbid disease which is likely to contribute to a life expectancy of six months or less should be considered for hospice eligibility. Comorbid diseases may include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <ol>",
"         <li>",
"          Chronic obstructive pulmonary disease",
"         </li>",
"         <li>",
"          Congestive heart failure",
"         </li>",
"         <li>",
"          Ischemic heart disease",
"         </li>",
"         <li>",
"          Diabetes mellitus",
"         </li>",
"         <li>",
"          Neurologic disease (CVA, ALS, MS, Parkinson)",
"         </li>",
"         <li>",
"          Renal failure",
"         </li>",
"         <li>",
"          Liver disease",
"         </li>",
"         <li>",
"          Neoplasia",
"         </li>",
"         <li>",
"          Acquired immune deficiency syndrome",
"         </li>",
"         <li>",
"          Dementia",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CVA: cerebrovascular accident or stroke; ALS: amyotrophic lateral sclerosis; MS: multiple sclerosis.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Centers for Medicare &amp; Medicaid Services. Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L32015)",
"     <a href=\"file://www.cms.gov/medicare-coverage-database/shared/handlers/highwire.ashx?url=file://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx@@@LCDId$$$32015***ContrId$$$236***ver$$$11***ContrVer$$$2***CntrctrSelected$$$236*2***Cntrctr$$$236***name$$$CGS+Administrators,+LLC+(15004,+HHH+MAC)***LCntrctr$$$236*2***bc$$$AgACAAIAQAAA***&amp;session=a2qgjyiqqk1bgt454ny2dr55&amp;kq=1056876468\" target=\"_blank\">",
"      file://www.cms.gov",
"     </a>",
"     (Accessed on January 10, 2013).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30268=[""].join("\n");
var outline_f29_35_30268=null;
var title_f29_35_30269="BTS diving guidelines a";
var content_f29_35_30269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73880&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of key points and recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The diving environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diving is an arduous underwater activity in which environmental conditions affect bodily structure and function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For",
"every 10 meters descent in sea water, ambient pressure increases by 100",
"kPa, equivalent to 1 atmosphere (1 bar). The volume of a given mass of",
"gas changes inversely in proportion to pressure. The gas in bodily",
"cavities such as the lungs, sinuses, middle ear and intestine is",
"therefore subject to compression during descent and expansion during",
"ascent. This may lead to tissue damage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partial pressure of",
"gases increases in direct proportion to the increase in ambient",
"pressure. Greater quantities of inert gas, mainly nitrogen, therefore",
"dissolve in tissues at depth and come out of solution on ascent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The density of inhaled gas increases with pressure, restricting breathing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immersion displaces blood from the periphery into the thorax, reducing lung volume.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work of breathing",
"increases due to a combination of increased gas density, increased",
"hydrostatic pressure, and altered respiratory mechanics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The underwater breathing apparatus adds dead space and increases resistance to breathing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        During diving, carbon dioxide retention may result from the above listed effects on the body.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potential risks of diving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General risks: panic, hypothermia, physical trauma, and drowning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equipment/technique",
"problems: hypoxia, hyperoxia, or poisoning by inappropriate gas",
"mixtures or contaminant gases may result from equipment malfunction or",
"poor dive planning. A",
"malfunctioning respiratory regulator may result in aspiration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barotrauma:",
"is caused by compression or expansion of gas filled spaces during",
"descent or ascent, respectively. Compression of the lungs during",
"descent may lead to alveolar exudation",
"and haemorrhage. Expansion of the lungs during ascent may cause lung",
"rupture leading to pneumothorax, pneumomediastinum, and arterial gas",
"embolism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompression illness:",
"may occur when gas, which has dissolved in tissues while at depth,",
"comes out of solution as bubbles. Clinical manifestations vary, the",
"most severe being cardiorespiratory and neurological.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of buoyancy control: is a cause of many accidents, usually when it leads to rapid uncontrolled ascent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It is also essential to consider comorbidities such as",
"diabetes and epilepsy which may influence capability for diving but are",
"outside the scope of this document.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The physician should bear the following general concepts in mind when assessing respiratory fitness to dive:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The subject may be required to swim in strong currents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The subject may be required to rescue a companion (dive buddy) in the event of an emergency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The diving environment is associated with a risk of lung rupture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The gas breathed by the diver may be very cold.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Buoyancy",
"control is essential and requires training, experience, and use of",
"appropriate equipment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The following recommendations are therefore made.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assessment of respiratory fitness to dive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the history,",
"particular attention should be paid to current respiratory symptoms,",
"previous history of lung disease including childhood history, previous",
"trauma to the chest, and previous episodes of pneumothorax.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory system examination should be performed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forced expiratory",
"volume in 1 second (FEV1), forced vital capacity (FVC), and peak",
"expiratory flow rate (PEF) should be measured. FEV1 and PEF should",
"normally be greater than 80% of predicted and the FEV1/FVC ratio",
"greater than 70 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine chest",
"radiography is not considered necessary in asymptomatic subjects with",
"no significant respiratory history and normal examination findings.",
"However, all professional divers, including recreational divers, who",
"plan to work as instructors are recommended by the Health and Safety",
"Executive to undergo chest radiography.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiography",
"is appropriate if there is a previous history of any significant",
"respiratory illness - for example, pleurisy, pneumonia, recurrent",
"respiratory infections, sarcoidosis, chest surgery or trauma,",
"pneumothorax - and those with current respiratory symptoms and/or",
"abnormal examination findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine measurement",
"of the expiratory flow-volume loop, exercise testing, or bronchial",
"provocation testing are not considered necessary although these tests",
"may be useful in specific cases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic CT",
"scanning, which has greater sensitivity than standard chest radiography",
"to detect lung structural abnormality, may be useful in specific areas.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Thorax, British Thoracic Society guidelines on respiratory aspects of fitness for diving, volume 58, pages 3-13, Copyright &copy; 2003, with permission from&nbsp;BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30269=[""].join("\n");
var outline_f29_35_30269=null;
var title_f29_35_30270="Pericardial effusion with tamponade short axis";
var content_f29_35_30270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/59345/shaxperi_conv.mp4?title=Pericardial+effusion+with+tamponade+short+axis\" style=\"width:249px;height:202px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal short axis view from a two-dimensional echocardiogram shows a very large pericardial effusion (PE) surrounding the left ventricle (LV) and right ventricle (RV) which is collapsed. The patient had severe hemodynamic compromise and tamponade physiology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30270=[""].join("\n");
var outline_f29_35_30270=null;
var title_f29_35_30271="Spleen aspirate 1";
var content_f29_35_30271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spleen aspirate 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_35_30271=[""].join("\n");
var outline_f29_35_30271=null;
